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By Yujie Yang 
 




The aryl hydrocarbon receptor (AHR) is a transcription factor first discovered 
to be activated by exogenous ligands, such as dioxins, and helps promote 
downstream gene (e.g. CYP1A1) transcription to metabolize the toxicants.  With the 
reports of various AHR targets genes, the expression levels and activities of AHR 
have been implicated in many physiological and pathological situations.  
Understanding how AHR protein level is regulated would provide more information to 
target AHR.  AHR stays in the cytosol in the absence of ligand in a complex with 
HSP90, p23 and XAP2.  After ligand activation, AHR translocates into the nucleus, 
fulfilling its transactivation function and then is finally degraded by proteasomes.  
Here, we discovered a new mechanism that controls basal AHR protein level: the 
selective autophagy.  Loss of AHR co-chaperone p23 leads to increased protein 
degradation of AHR through autophagy in HeLa cells.  Inhibition of autophagy using 
several inhibitors (chloroquine, bafilomycin A1 or 3-methyladenine) increased AHR 
protein levels.  Knocking down of key macroautophagy protein LC3B increases AHR 
protein levels and decreases the responsiveness of AHR to CQ treatment.  The 
interaction between AHR and LC3B as well as AHR and autophagy receptor p62 
were confirmed in vitro and in situ.  AHR is found to be lysine (K) 63-ubiquitinated in 
HeLa cells, which is a common signal for the autophagy-lysosomal degradation.  
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We also discovered that AHR is controlled by glycogen synthase kinase 3β 
(GSK3β) phosphorylation.  Inhibition of GSK3β activity or its expression level 
increased AHR protein levels while expression of HA tagged-GSK3β lowers AHR 
protein levels.  AHR protein level is regulated through autophagy.  We confirmed the 
GSK3β-mediated phosphorylation of AHR by phos-tag gel electrophoresis couples 
with Western blot analysis and identified three putative phosphorylation sites of AHR 
in the C-terminal half of AHR sequence.  Moreover, phosphorylated AHR constitutes 
the active pool for transactivation and phosphorylation tagged AHR for the 
autophagy-lysosomal degradation, which may act as way to limit its function. 
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CHAPTER 1: INTRODUCTION 
 
The Aryl Hydrocarbon Receptor 
The aryl hydrocarbon receptor (AHR) was first identified by Alan Poland’s 
laboratory in 1976 (Poland, Glover, & Kende, 1976) and is originally recognized as a 
receptor/transcription factor in response to environmental toxicants such as dioxins 
and polycyclic aromatic hydrocarbons.  Since then, more roles of AHR in 
physiological and pathological situations such as organ development, immune 
responses, nervous system homeostasis, and carcinogenesis have been uncovered.  
Not surprisingly, AHR has become a promising target for the treatment of diseases 
such as autoimmune diseases, inflammation, and cancers. However, the AHR 
function is often ligand-, cell context-, and tissue-specific, confounding the feasibility 
of targeting AHR for rational drug design.  Understanding the basic biology of AHR 
would provide much-needed information for effective modulation of the AHR 
function. 
AHR Complex and Classical Signaling Pathway 
AHR belongs to the basic helix-loop-helix-PER-ARNT-SIM (bHLH-PAS) 
family, which contains dimeric transcription factors that share similar N-terminal 
sequence to AHR nuclear translocator (ARNT), and two Drosophila proteins “single-
minded” (SIM; involved in neuronal development) and “periodic” (PER; a circadian 
regulator), hence named as PAS domain in 1991 (Crews, Thomas, & Goodman, 
1988; Hoffman et al., 1991; Konopka & Benzer, 1971; Reyes, Reisz-Porszasz, & 
Hankinson, 1992).  Figure 1.1 below showed the domain structure of AHR protein 
(Faber, Soshilov, Giani Tagliabue, Bonati, & Denison, 2018; C. A. Flaveny & 
Perdew, 2009; Fukunaga, Probst, Reisz-Porszasz, & Hankinson, 1995; Ikuta, 
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Figure 1.1.  Structure of AHR domains  
Eguchi, Tachibana, Yoneda, & Kawajiri, 1998; Schulte, Green, Wilz, Platten, & 
Daumke, 2017).  The N-terminal bHLH domain is responsible for DNA binding, 
followed by two tandem PAS domains, which contain two reverted repeats of 51-
amino acids in length conserved in PAS family proteins (PAS-A and PAS-B), 
contributing to dimerization and ligand binding.  The C-terminal half of AHR contains 
a transactivation domain (TAD) consisting of three separable regions, namely acidic, 
glutamine-rich, and proline/serine/threonine-rich motifs (Fukunaga et al., 1995).  The 
ligand binding domain (LBD) of AHR locates in PAS-B domain (Burbach, Poland, & 
Bradfield, 1992).  However, soluble AHR constructs containing PAS-B domain are 
hard to purify in large amounts and the crystal structure has not been reported yet.  
Knowing the structural data of LBD may provide better understanding of the ligand-
specific responses of AHR.   
   
                                                        .  Q, glutamine; P, proline; S, serine; T, 
threonine; TAD, transactivation domain. 
 
AHR-ARNT heterodimer forms via three interfaces located in bHLH and PAS-
A domains.  Although PAS-B domain is reported to be involved in dimerization of 
other PAS proteins, AHR: ARNT is stable without PAS-B domain (Schulte et al., 
2017).  AHR construct lacking the PAS-B domain is constitutively active in mice 
(Andersson et al., 2002), suggesting that ligand binding is important for the 
bHLH PAS-A PAS-B Acidic  Q-rich        P/S/T-rich1 848
33 87 111 273 275 386 490 TAD 805





localization of AHR but not for the transactivation function and PAS-B domain is not 
required for dimerization.  It is more like that PAS-B functions as a regulation domain 
for dimerization.  Residues 13-39 act as the nuclear localization signal (NLS), which 
contains two cluster of basic amino acids connected by a spacer of 17 amino acids 
in length.  Leucine-rich sequence (amino acids 55-75) is reported to function as the 
nuclear export signal (NES) (Ikuta et al., 1998).  Differences in structures of AHR 
may explain the species- and strain- differences of AHR responsiveness.  The 
C57BL/6J mice expressing the mAHRb allele showed a ~10-fold higher affinity for 
AHR ligands comparing to DBA mice mAHRd allele strain and human AHR.  The N-
terminal sequence of AHR in different strains and species are highly conserved while 
the C-terminal transactivation domains (TAD) share less similarity (C. A. Flaveny & 
Perdew, 2009).  It is reported that the variable TAD can result in different co-
activators recruited and thus may regulate different downstream gene expression (C. 
Flaveny, Reen, Kusnadi, & Perdew, 2008). 
AHR stays in the cytoplasm in the absence of ligand treatment in a complex 
with two molecules of HSP90, one molecule of its co-chaperone p23 and one 
molecule of XAP2.  HSP90 is required for the correct folding of AHR and stabilize 
AHR in an inactive form in the cytoplasm.  Binding with HSP90 also maintains AHR 
in an accessible conformation for ligand binding (Antonsson, Whitelaw, McGuire, 
Gustafsson, & Poellinger, 1995; Coumailleau, Poellinger, Gustafsson, & Whitelaw, 
1995; Pongratz, Mason, & Poellinger, 1992; Whitelaw, McGuire, Picard, Gustafsson, 
& Poellinger, 1995).  The roles of p23 in AHR complex are not clearly defined.  It is 
reported that p23 can stabilize the AHR complex and help XAP2 in AHR cytoplasmic 
retention (A Kazlauskas, Poellinger, & Pongratz, 1999; A Kazlauskas, Sundström, 
Poellinger, & Pongratz, 2001; Arunas Kazlauskas, Poellinger, & Pongratz, 2000).  As 
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the co-chaperone protein of HSP90, p23 can interact with the ATP-bound HSP90 
and stabilize the conformation of HSP90 in complex with its client proteins.  Whether 
this is also true for AHR-HSP90 complex has not been confirmed.  Studies in yeast 
using yeast p23 homolog Sba1 support this ATP-dependent HSP90 stabilization 
(Cox & Miller  3rd, 2004).  Our lab previously showed that AHR protein level is 
decreased when p23 is knocked down in multiple cell lines and this protection role of 
p23 is HSP90-binding independent (P. M. Nguyen et al., 2012a; Pappas et al., 
2018).  p23 is also reported to help with nuclear import, HSP90 release from AHR 
complex and the formation of AHR/ARNT/DRE complex in ligand activation (A 
Kazlauskas et al., 1999; Shetty, Bhagwat, & Chan, 2003).  However, the effects of 
p23 on AHR signaling were not observed in the p23-null mouse embryo (C. Flaveny, 
Perdew, & Miller  3rd, 2009).  XAP2 can stabilize AHR complex and retain AHR in 
the cytoplasm (Arunas Kazlauskas et al., 2000; LaPres, Glover, Dunham, Bunger, & 
Bradfield, 2000; Meyer, Petrulis, & Perdew, 2000; Petrulis, Hord, & Perdew, 2000).  
It has been reported that XAP2 may protect AHR from ubiquitination and sequential 
proteasomal degradation by inhibition of E3 ligase C-terminal hsp70-interacting 
protein (CHIP) in constitutively nuclear localized AHR expressing stable 293T cell 
lines (Michael J Lees, Peet, & Whitelaw, 2003) and in vitro studies, even though 
AHR protein levels were not altered after CHIP knockdown in Hepa1c1c7 cells 
(Morales & Perdew, 2007).  There are conflicting data on whether XAP2 can 
influence AHR signaling function. 
Ligand binding triggers the conformational change and exposes the nuclear 
localization signal (NLS) in the N-terminus of AHR, leading the AHR complex 
translocate into the nucleus.  Once in the nucleus, the AHR complex dissociates and 
AHR heterodimerizes with AHR nuclear translocator (ARNT).  Recently, Denison’s 
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group reported multi-step events and ligand-dependent transitional states that attach 
more mechanistic details between the ligand binding and transactivation (A. A. 
Soshilov, Motta, Bonati, & Denison, 2020).  Since there is no structural information 
available for AHR complex, e.g. AHR: HSP90 binding structure, they proposed 
HSP90 “closed” and “open” conformation based on the reported Cryo-EM structure 
of HSP90: CDK4 (HSP90 client protein) (Verba et al., 2016).  Binding of HSP90 in 
the PAS-B domain stabilizes AHR in an inactive state and the dimer of HSP90 is in a 
closed conformation clipping AHR.  Upon ligand binding, the PAS-B domain 
conformation changes and the HSP90 dimer is in an open mode, in which NLS is 
exposed, leading to AHR translocation.  In the meantime, PAS-A domain is more 
exposed (A. Soshilov & Denison, 2008), which may facilitate the binding of ARNT in 
the nucleus.  ARNT binds to the AHR complex in the nucleus and forms a 
transitional state, which can only be captured in the presence of HSP90 binding 
stabilizer sodium molybdate.  Then ARNT heterodimerization with AHR will quickly 
displaces HSP90 and dissociates AHR complex.  The heterodimer then binds to the 
dioxin response element (DRE) in the enhancer region of the downstream target 
genes and promotes transcription.  The minimal recognized sequence for DRE is 5’-
NGCGTG-3’ (N stands for any nucleotide), where AHR binds to the 5’ part (GC) and 
ARNT recognizes the 3’-half GTG (Swanson, Chan, & Bradfield, 1995; Yao & 
Denison, 1992).   
One of the classical gene products and also the prototype target of AHR 
transactivation is CYP1A1, which is widely used as a biomarker for AHR function.  It 
is widely expressed in various tissues not at a constitutively high level but is highly 
inducible (up to ~100 fold) (Mescher & Haarmann-Stemmann, 2018).  Other 
metabolism enzymes such as CYP1A2, CYP1B1, UGT and NQO1 are also reported 
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to be AHR downstream products (Favreau & Pickett, 1991; Strom, Postlind, & Tukey, 
1992; Yueh et al., 2003; L. Zhang, Savas, Alexander, & Jefcoate, 1998). 
AHR repressor (AHRR) is a negative regulator of AHR function, and its 
expression is transactivated by AHR, which is a key mechanism for limiting AHR 
excessive activation.  AHRR also belongs to the bHLH-PAS protein family.  The 
sequence of bHLH and PAS-A domains in AHRR shares about 55% similarity to that 
in AHR (Sakurai, Shimizu, & Ohto, 2017; Schulte et al., 2017) while AHRR does not 
have PAS-B domain (Mimura, Ema, Sogawa, & Fujii-Kuriyama, 1999).  The 
mechanism of AHRR repression is not clearly defined.  There are several models 
proposed, of which the most widely accepted one is the competitive mechanism for 
ARNT and DRE binding (Mimura et al., 1999).  The residues involved in the 
interaction to DRE region and ARNT are mostly conserved between AHR and 
AHRR.  The crystal structure of human AHRR bHLH-PAS-A: bovine ARNT bHLH-
PAS-A-PAS-B and human AHR bHLH-PAS-A: mouse ARNT bHLH-PAS-A showed 
that domain conformation and interaction interface were rather comparable between 
those two complexes (Sakurai et al., 2017; Schulte et al., 2017).  These data support 
that AHRR can repress AHR function via competitive binding to ARNT and DRE 
DNA.  Another competition mechanism presented by Evans et al. proposed that 
AHRR can also compete with AHR for binding some unknown transcription factors 
(Evans et al., 2008).  Repression is also reported to be mediated through 
SUMOylation of the C-terminal AHRR, which recruits co-repressors to the promoter 
region of target genes (Oshima, Mimura, Sekine, Okawa, & Fujii-Kuriyama, 2009). 
This SUMOylation is not observed in AHR proteins.  The crystal structure analysis 
revealed an interaction interface between AHRR PAS-A and ARNT PAS-B, unique in 
PAS protein heterodimer (others reported are PAS-B to PAS-B homotypic 
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interaction) and the residues involved and the corresponding secondary structures in 
AHRR are not found in AHR (Sakurai et al., 2017), which might play roles for the 
unique SUMO modification.  
Another mechanism to limit AHR transactivation is its quick degradation after 
ligand activation.  Ligand binding shortens AHR half-life and promotes AHR 
ubiquitination, which tagged AHR for proteasomal degradation (Q. Ma & Baldwin, 
2000; Roberts & Whitelaw, 1999b).  It is reported that this degradation happens 
following nuclear export (Davarinos & Pollenz, 1999).  Dissociation of HSP90 from 
AHR that mimics the transformation status of AHR, while having a different 
conformation as ligand bound-AHR complex, also promotes AHR for proteasomal 
degradation (M J Lees & Whitelaw, 1999).  This degradation is reported to happen 
both in the nucleus and cytoplasm (Song & Pollenz, 2002, 2003). 
Roles of AHR in Diseases   
The development of AHR deficient mice models identify various physiological 
and pathological roles for AHR.  Of all the important roles of AHR, its influence in 
autoimmune diseases, gut inflammation and carcinogenesis show promising 
druggability.  
AHR and immune responses.  Within all T cell subsets, TH17 cells and 
regulatory T (Treg) cells show the highest AHR expression levels when comparing to 
others (Rothhammer & Quintana, 2019).  AHR expression levels increase during 
TH17 development (Quintana et al., 2008) and AHR activation influences the 
differentiation and conversion between pathogenic (pro-inflammatory) and non-
pathogenic (anti-inflammatory) TH17 cells, depending on specific stimuli, such as IL-
23.  IL-23 exposure induces pathogenic TH17 differentiation, signatured by 
production of TGF-β3, while differentiation in response to IL-6 and TGFβ still 
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possess some IL-10 producing anti-inflammatory activities (Y. Lee et al., 2012; 
McGeachy et al., 2007).  It has been reported that AHR endogenous ligand 6-
formylindolo[3,2-b]carbazole (FICZ) can promote the pathogenic TH17 cells 
generation, which significantly worsens the mice model for multiple sclerosis, 
experimental autoimmune encephalomyelitis (EAE) (Quintana et al., 2008).  Another 
AHR endogenous ligand 2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl 
ester (ITE) is reported to inhibit the TH17 differentiation and favoring the IL-10 
production by Treg cells and dendritic cells in EAE and allergic rhinitis (Quintana et 
al., 2008; Wei et al., 2014).  Together with TGFβ signaling, AHR also mediates the 
transdifferentiation of TH17 cells into anti-inflammatory Treg cells (TR1 cells) (Gagliani 
et al., 2015).  AHR activation by TCDD and ITE can affect the expression of 
cytokines such as IL-10 and promote the differentiation of immune suppressive TR1 
cells and FOXP3+ Treg cells (Gandhi et al., 2010; Quintana et al., 2008).  AHR 
activation can also affect dendritic cells (DC), mostly contributing to anti-
inflammatory activities in differentiated DCs.  AHR signaling can induce tolerogenic 
DCs, promoting the generation of Treg cells and inhibiting pathogenic TH17 
differentiation (N. Baba et al., 2012; Benson & Shepherd, 2011; Hauben et al., 2008; 
N. T. Nguyen et al., 2010).   
The effects of AHR signaling on immune cells explain the reported AHR roles 
in mucosal/surface sites (lung, skin, and gut) inflammation and autoimmune 
diseases, neurodegenerative disorders, transplantation tolerance and neoplastic 
diseases.  The gut homeostasis involves a complex network of epithelial cells and 
stromal cells, establishing healthy structural barriers and local immune system.  
Other than AHR roles in intraepithelial lymphocytes, intestinal DCs and innate 
lymphoid cells, AHR also controls intestinal epithelial cell regeneration and helps 
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maintain the intestinal barrier integrity (Metidji et al., 2018).  Together with AHR 
agonists from diet and host metabolism, microbiome metabolism also provides AHR 
ligands or AHR ligand precursors that can be further metabolized by the host, 
playing important roles in gut inflammation, as well as anatomically distant tissues 
such as the gut-brain axis.  AHR activation by agonists derived from microbiome 
metabolites is reported to suppress the pro-inflammatory activities of microglia and 
astrocytes, improving central nervous system inflammation and neurodegeneration 
(Rothhammer et al., 2018, 2016).  Moreover, impaired AHR agonists production by 
microbiome are reported in inflammatory bowel diseases (Lamas et al., 2016), 
metabolic syndrome (Natividad et al., 2018) and multiple sclerosis (Rothhammer et 
al., 2017).   
AHR in cancer.  Alteration of AHR expression levels and activities were 
observed in various cancer types (Kolluri, Jin, & Safe, 2017; Murray, Patterson, & 
Perdew, 2014).  Both oncogenic and tumor suppressor roles of AHR were reported, 
largely dependent on cell context, ligands encountered and tumor stages.  Parallel 
with the protective roles of AHR in immune response mentioned above, especially in 
the gut-brain axis, AHR was reported to show tumor suppressor effects in intestinal 
and colon cancer.  AHR-/- mice were reported to be more prone to cecal cancer due 
to abnormal accumulation of β-catenin (Ikuta et al., 2013; Kawajiri et al., 2009).  
Feeding the APCmin/+AHR+/- mice with AHR ligands IAA, I3C of natural-AHR ligands 
containing diet significantly decreases the incidence of intestinal tumors as well as 
tumor numbers in the small intestine.  Ahr null mice showed increased incidence of 
colitis-associated colorectal tumor compared to wild type mice.  AHR ligand I3C diet 
can significantly decrease the tumor numbers in wild type but not ahr null mice 
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(Díaz-Díaz et al., 2016), confirming the protective role of AHR in intestinal and colon 
tumorigenesis.   
A contrasting role of AHR in brain tumor was proposed.  Gramatzki et al. 
reported that AHR is expressed in glioma in vivo.  Antagonism of AHR by CH223191 
reduced glioma tumor growth and invasiveness through TGFβ/Smad signaling 
(Gramatzki et al., 2009).  AHR is activated by its endogenous ligand kynurenine, 
produced by highly expressed tryptophan-2,3-dioxygenase (TDO) in glioma cells and 
acts in an autocrine manner.  The TDO-AHR signaling promotes glioma cell motility 
and clonogenic survival (Opitz et al., 2011).  TDO-kynurenine-AHR axis can also 
promote stage 4 glioma (glioblastoma) progression through recruitment of 
macrophages.  AHR signaling in tumor associated macrophages (TAM) promotes its 
polarization to immunosuppressive M2 macrophages, which can impair CD8+ tumor-
infiltrating T cell function.  The kynurenine expression level, AHR-related gene 
expression levels as well as TAM infiltration are higher in glioblastoma.  Higher 
mortality is correlated with higher AHR expression level (Takenaka et al., 2019).  
However, Jin et al. reported that the inhibitory effect of CH223191 is AHR-
independent.  Based on their data in established and patient-derived glioma cells, 
kynurenine effect is cell context- and response-dependent and AHR plays a tumor-
suppressive role in glioblastoma (Jin et al., 2019).   
Most of the studies on AHR roles in breast cancer support that AHR is 
protective against tumor growth as well as invasion and metastasis (Kolluri et al., 
2017).  Higher AHR expression level is associated with improved survival rate and 
decreased distant metastasis (O’Donnell, Koch, Bisson, Jang, & Kolluri, 2014).  AHR 
is reported to show high expression level in pancreatic cancer while activation of 
AHR by alternate alkyl substituted chlorinated dibenzofurans (alkyl-PCDFs) and 
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diindolylmethane (DIM) can inhibit pancreatic cancer cell growth (Koliopanos et al., 
2002).  In prostate cancer, the roles of AHR are dependent on androgen receptor 
(AR).  Upregulation of AHR protein level upon E3 ligase subunit β-transducin repeat 
containing proteins (β-TrCP) inhibition reduced tumor growth in AR-positive prostate 
cancer cells (Gluschnaider et al., 2010) while it shows pro-oncogenic effects in AR-
negative or AR signaling-independent prostate cancer cells (Haque, Francis, & 
Sehgal, 2005; Tran, Richmond, Aaron, & Powell, 2013).  The effects of AHR 
expression and/or activity in lung and liver cancer cells have mixed results of pro- 
and anti-cancer roles (Kolluri et al., 2017).  The underlying mechanisms of AHR in 
various hallmarks of tumorigenesis, including roles in tumor microenvironment, 
cancer stem cell development, cancer cell proliferation and cell cycle, metastasis 
and immunity, were well summarized in several review papers (Feng, Cao, & Wang, 
2013; Murray et al., 2014).  Given the complexed, but important roles of AHR in 
cancer, Stephen Safe lab first proposed the concept of non-toxic selective AHR 
modulators (SAhRM) to target AHR in a tissue-specific manner (Safe, Lee, & Jin, 
2013), which needs more comprehensive and extensive understanding of regulation 
of AHR expression and its subsequent signaling. 
Autophagy 
Autophagy is a highly conserved pathway to maintain cellular homeostasis.  
By degrading cellular contents, including aggregated proteins, lipid droplets, 
glycogen, organelles, pathogens and etc., cells can recycle nutrients and respond to 
different stress situations.  Therefore, autophagy plays important roles in human 
diseases, such as neurodegeneration (Nixon, 2013),  multiple cancers (Levy, 
Towers, & Thorburn, 2017), inflammation and infections (Levine, Mizushima, & 
Virgin, 2011).  There are three major types of autophagy: macroautophagy, 
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microautophagy and chaperone-mediated autophagy.  Chaperone-mediated 
autophagy (CMA) is a selective degradation pathway for proteins with a KFERQ-like 
motif, which can be recognized by Hsc70 and delivered to lysosomes via LAMP-2A.  
Microautophagy is less studied than the other two types of autophagy.  Substrates 
are directly sequestered in manners of lysosomal protrusion/invagination or 
endosomal invagination for degradation in the lysosome (Oku & Sakai, 2018).  
Macroautophagy involves the formation of a double-membrane structure, 
autophagosome, and its fusion with the lysosome.  My projects mostly studied the 
involvement of macroautophagy in the regulation of AHR. 
Macroautophagy 
Since Christian de Duve discovered lysosomes in rat liver and defined 
autophagy in 1960s (DE DUVE, PRESSMAN, GIANETTO, WATTIAUX, & 
APPELMANS, 1955; Klionsky, 2008), there have been many important findings of 
autophagy reported in many different species, especially the research performed in 
yeast.  Macroautophagy was initially viewed as a non-selective, self-eating process 
triggered by stresses such as starvation.  In the recent two decades, there have 
been more and more types of selective autophagy identified, as means of selective 
degradation for protein aggregates (aggrephagy), fragments of ER (ER-phagy), 
mitochondria (mitophagy), ribosome (ribophagy), glycogen (glycophagy), lipid 
droplets (lipophagy), and other organelles or cell components (Kirkin, 2020).  The 
most critical and typical event in macroautophagy (referred to as autophagy 
thereafter) is the formation of autophagosome for the sequestration of cellular 
contents.  It is initiated from the nucleation of autophagy-related proteins and cargo 
proteins.  The cup-shaped structure then elongates and seals to form the double-
membrane autophagosome.  Upon fusion with lysosomes, the inner membrane and 
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the engulfed contents of the autophagosome are degraded by lysosomal hydrolases.  
Autophagy is a well-organized hierarchical process. Depending on how autophagy 
happens, as a basal event or induced by different stimuli, the autophagy-related 
gene (Atg) proteins employed, as well as the sequence of events, can be slightly 
different. But they share the similar machinery. 
Key modules of macroautophagy machinery.  There are five key modules 
for the macroautophagy machinery (table x): (1) Atg1 or ULK1 complex; (2) PI3K 
complex; (3) Atg2-Atg18 or PI3P-binding complex; (4) the Atg9 cycling system; (5) 
Atg12-Atg5-Atg16(L) and Atg8 (or LC3B) conjugation system.  The diagram of the 
involvement of those modules in selective autophagy is shown under the selective 
autophagy section (Figure 1.2). 
Atg1/ULK1 kinase complex.  The Atg1/ULK1 (the homolog of Atg1 in 
mammals) complex is the farthest upstream module of core autophagy machinery.  
The Atg1 complex in yeast is mainly comprised of Atg1, Atg11, Atg13, Atg17, Atg29 
and Atg31; ULK1 (or ULK2), ATG13, FIP200 and ATG101 form the ULK1 complex in 
mammals (Mizushima, 2010).  Initiation of autophagy starts from the activation of 
Atg1 complex. Atg1 (or ULK1/2 in mammalian cells) is a Ser/Thr kinase, which can 
be triggered to be activated through autophosphorylation.  Starvation-induced 
autophagy activates Atg1 by target of rapamycin complex 1 (TORC1), which is 
responsible for upstream signal sensing, including amino acid, glucose, growth 
factors (e.g. insulin) as well as oxygen (Sengupta, Peterson, & Sabatini, 2010).  
Energy-sensing AMPK pathway is also reported to regulate autophagy independent 
of mTORC1 (Shang & Wang, 2011).  When cells are under stress conditions, such 
as starvation, TORC1 is inhibited, leading to the hypophosphorylation of its 
downstream substrate Atg13.  Dephosphorylation of Atg13 promotes its interaction 
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with Atg1 and Atg17-Atg29-Atg31 complex.  In mammalian cells, ULK1/2, ATG13, 
FIP200 and Atg101 form stable complexes independent of nutrient status and this 
complex interacts directly with mTORC1.  Additional proteins are then recruited and 
trigger downstream steps.  Cargo-induced selective autophagy, basal events that 
happen in nutrient-rich condition, bypass mTORC1 regulation.  Cargo proteins are 
required for activation of the Atg1 complex.  Cells lacking either cargo protein, 
autophagy receptor, or Atg11, reduced the level of autophosphorylated Atg1 
(Kamber, Shoemaker, & Denic, 2015).  Atg11 is a key scaffold protein in cargo-
induced selective autophagy by bridging the cargo-autophagy receptor and Atg1 
complex.  FIP200 is proposed to be the mammalian counterpart for Atg17 and Atg11 
(Hara et al., 2008).  The ULK1 kinase complex triggers downstream autophagic 
events at least in part by phosphorylation.  Numerous autophagy-related proteins are 
reported to be ULK1 substrates, including ULK1 itself, class III PI3K complex 
subunits (PI3KC3-C1), and Atg9 (Papinski et al., 2014).  It is reported that following 
activation, ULK1 autophosphorylation promotes its ubiquitination and proteasomal 
degradation via Cul3-KLHL20 ubiquitin ligase, helping in autophagy termination to 
maintain homeostasis (Liu et al., 2016). 
The class III Phosphatidylinositol 3-kinase (PI3KC3) complex.  The 
PI3KC3 is downstream of ULK1 complex activation.  The net result of PI3KC3 
activity is the production of phosphatidylinositol 3-phosphate (PtdIns3P), a signaling 
lipid on phagophore membranes.  There are three classes of PI3K complexes (I, II 
and III).  The class I PI3K complex (PI3KC1) is reported to inhibit autophagy while 
PI3KC3 activates autophagy (Petiot, Ogier-Denis, Blommaart, Meijer, & Codogno, 
2000).  VPS34-VPS15 is the core of the complex, of which VPS34 being the catalytic 
subunit of the kinase.  Together with Beclin1 (or Atg6/Vps30), ATG14 and NRBF2 
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(or Atg38), they form complex I (PI3KC3-C1), which is more studied and reported to 
be involved in autophagosome initiation, while VPS34-VPS15 and Beclin1 can also 
assembly with UVRAG (or Vps38) instead of ATG14, forming complex II (PI3KC3-
C2).  The conformation of the PI3KC3 complex is highly dynamic, of which the 
“dislodged” conformation of VPS34 being the catalytically active form.  This is 
reported to be negatively regulated by VPS15 via binding to the lipid kinase domain 
of VPS34 (Stjepanovic, Baskaran, Lin, & Hurley, 2017).  Vps15 also serves as a 
“bridge”, connecting the regulatory subcomplexes, such as Beclin-ATG14, to the 
catalytic subunit, communicating the regulatory signals to control PI3KC3 activity.  
The VPS34 catalytic domain is not directly contacted to the Beclin1-ATG14 
regulatory sequences.  Thus, the assembly of the complex is dependent on VPS15.  
Beclin1 is an important regulatory subunit of PI3KC3 complex.  It can be 
phosphorylated and dephosphorylated by multiple kinases, including ULK1 
(activated phosphorylation), and phosphatases (Hurley & Young, 2017).  Another 
important regulatory sequence in Beclin1 is the binding sequence for Bcl-2, which 
inhibits the activity of the PI3KC3 complex.  ATG14 is exclusively contained in 
PI3KC3-C1 and is important for its localization to the phagophore membrane via the 
amphipathic lipid packing sensor (ALPS) motif in the Barkor autophagosome 
targeting sequence (BATS) domain (Brier et al., 2019).  The ALPS motif helps 
PI3KC3-C1 sensing the highly curved lipid structure on the phagophore membrane 
(Antonny, 2011; Brier et al., 2019).  The PI3KC3-C2 is reported to be less active in 
targeting the highly curved structure, which might be the reason that PI3KC3-C2 is 
not responsible for production of PtdIns3P and the stimulation of LC3 lipidation (Brier 
et al., 2019).  UVRAG acts as a metabolic switch for PI3KC3-C1. Its phosphorylation 
suppresses the complex activity while dephosphorylation promotes the complex 
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assembly (X. Ma et al., 2017).  The PI3KC3-C2 is defined by the replacement of 
UVRAG instead of ATG14 (no NRBF2 either).  The exact roles of PI3KC3-C2 are not 
clear, but it is reported to be involved in the later stages of autophagosome 
maturation and endocytic trafficking (Liang et al., 2008). 
The PI3P effectors and ATG9 trafficking system.  Double FYVE-containing 
protein 1 (DFCP1) and WIPI proteins (WIPI 1/2/4) are PI3P effectors, helping  
promote the elongation of isolation membrane.  WIPIs (WIPI2 particularly) localize to 
the highly curved opening edge of the isolation membrane (Graef, Friedman, 
Graham, Babu, & Nunnari, 2013; Suzuki, Akioka, Kondo-Kakuta, Yamamoto, & 
Ohsumi, 2013), adjacent to DFCP1, through binding to PI3P.  WIPIs proper 
recruitment and functions are dependent on ATG9.  ATG9 is the only 
transmembrane protein recruited to the phagophore, together with WIPIs (Atg2-
Atg18 complex as yeast homolog) the ATG9 vesicles provide membrane sources for 
autophagosome formation (Carlsson & Simonsen, 2015).  This elongation of 
phagophore membrane provides support for LC3 lipid conjugation (Brier et al., 
2019).  WIPI2 also interacts with ATG16L, recruiting the ATG12-ATG5-ATG16L 
complex, thus acting as a scaffold protein for LC3 lipidation (Proikas-Cezanne, 
Takacs, Dönnes, & Kohlbacher, 2015).   
ATG12-ATG5-ATG16L and LC3-PE conjugation systems.  These two 
conjugation systems are important for the expansion and closure of the isolation 
membrane, functioning at the late steps of autophagosome formation.  Microtubule 
associated protein 1 light chain 3 (MAP1LC3 or LC3) is synthesized as a precursor 
protein.  It is then processed by a cysteine protease ATG4 and the resulting C-
terminal glycine-exposed form is termed as LC3-I.  LC3-I is first activated by Atg7 
(E1-like) and then transferred to Atg3 (E2-like).  The ATG12-ATG5-ATG16L complex 
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acts as the E3 ligase for LC3, linking it to an amino group of 
phosphatidylethanolamine (PE), a major phospholipid on the (isolation) membrane 
(Ichimura et al., 2000), referred as LC3-II.  There are three members of LC3 family: 
LC3A, LC3B and LC3C.  Among them, LC3B is the most studied and is a well-
accepted marker for autophagy activity.  LC3A and LC3C are reported to share high 
sequence similarity with LC3B, as well as some location and functional similarities 
and differences (Koukourakis et al., 2015; Schaaf, Keulers, Vooijs, & Rouschop, 
2016).   ATG4 deconjugates LC3-PE on the outer membrane, while the conjugated 
LC3 on the inner membrane, are degraded together with cargos in the lysosome.  
Deficiency in Atg4 deconjugation activity will lead to incomplete, elongated 
autophagosomes in yeast (U. Nair et al., 2012).  ATG12 is synthesized as a C-
terminal glycine-exposed form.  It is activated by ATG7 (E1-like), then transferred to 
ATG10 (E2-like) and finally conjugated with ATG5.  This ATG12-ATG5 conjugate 
then form a complex with ATG16L in a 2:2:2 stoichiometric manner (Fujioka, Noda, 
Nakatogawa, Ohsumi, & Inagaki, 2010).  This complex helps LC3 lipidation as an E3 
ligase.  ATG16L in this complex promotes its localization to the isolation membrane, 
via WIPI2 binding, and determines the site of LC3 lipidation.  Once being conjugated 
to the isolation membrane, LC3-II maintains involvement in the whole autophagy 
process, making it a good indicator of autophagosome formation and autophagic flux 
(Mizushima, Yoshimori, & Levine, 2010).  
Selective autophagy and aggrephagy.  In the early 2000s, the concept that 
cargos can be degraded in a highly selective way started to gain more attention.  
Autophagic degradation is not triggered by stimuli, such as starvation, but induced by 
the cargo itself.  For example, deletion of the cargo protein prApe1 in S. cerevisiae 
impaired the organization of phagophore under growing conditions, but it did not 
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affect the formation of autophagosome during starvation (Shintani & Klionsky, 2004).  
The machinery involved is similar to the stimuli-induced autophagy, as described 
above, but the sequential processes are not the same.  It is reported that LC3 
recruitment requires the intact lipid conjugation system but is independent of other 
core ATG proteins in Salmonella xenophagy (Kageyama et al., 2011).  The LC3-
interacting region (LIR) motif was found in ULK1 (Alemu et al., 2012) and all key 
components of PI3KC3 (Birgisdottir et al., 2019).  Their anchoring to the phagophore 
require the recruitment of LC3.  It is reported recently by Marten’s group that the 
cargo receptor p62 can recruit both LC3 and ULK1 complexes, via direct binding with 
FIP200 in a mutually exclusive way (Turco et al., 2019), promoting the formation of 
autophagosome.  Therefore, the proposed cargo-induced model for selective 
autophagy is as follows (Figure 1.2), though more information is needed to clarify the 
details of hierarchy and ATG proteins involved: (1) The aggregation of cargo proteins 
with or without modification (e.g. ubiquitination); (2) The binding of cargo receptor to 
cargos; (3) Recruitment of LC3-PE and other ATG proteins; (4) Formation and 
expansion of local isolation membrane; (5) Autophagosome formation and fusion 
with lysosome.  The size of the autophagosome is in the range of 0.1-1.5 μm, 
depending on the cell type and inducing signal (Rogov, Dötsch, Johansen, & Kirkin, 
2014).  The size of autophagosomes in selective autophagy is reported to be smaller 
than that in starvation-induced autophagy.  The close apposition between cargos 
and autophagosome membrane helps to exclude the non-specific materials during 
sequestration whereas in starvation-induced autophagy, random materials could be 
introduced into the autophagosome (M. Baba, Takeshige, Baba, & Ohsumi, 1994; 
Sawa-Makarska et al., 2014).  The degradation of cargo proteins by selective 
macroautophagy is termed as aggrephagy.  The cargo proteins and/or the cargo 
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Figure 1.2.  Phagophore assembly and isolation membrane expansion in selective 
autophagy 
 
receptors need to be aggregated/oligomeric to be delivered into the autolysosome.  
The aggregated or oligomerized proteins can provide larger surface for multiple 
binding of cargo receptors and/or ATG proteins, which offer higher avidity and may 
concentrate ubiquitin like proteins (UBL) for further autophagic events amplification.   
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Selectivity is mainly conveyed by autophagy cargo receptors or selective 
autophagy receptors (SAR).  They specifically bind to autophagy cargos and tether 
autophagy machinery to the cargos via the simultaneous binding to LC3B.  The 
binding of cargo receptor to LC3B is dependent on the LC3-interacting region (LIR) 
of the receptor.  The canonical LIR motif shares the common sequence W/F/Y-X-X-
L/I/V, binding to the hydrophobic pockets of LC3.  There are usually acidic residues 
or serine/threonine phosphorylation upstream of the LIR in near proximity, 
























receptor, in most cases reported, is ubiquitin dependent.  Ubiquitin-independent 
cargo-receptor direct bindings are also reported (see details in review (Kirkin, 2020)).  
Those reported proteins are either not mammalian proteins or not involved in 
aggrephagy, but other subtypes, such as mitophagy or ER-phagy.  Some proteins 
containing LIR motifs can be degraded in a SAR-independent way via direct binding 
to LC3.  
Protein ubiquitination codes for degradation or downstream signaling.  
Different linkages of ubiquitin direct the ubiquitinated proteins to different degradation 
pathways: K63 ubiquitination is usually recognized by cargo receptors to undergo 
lysosomal degradation whereas proteins with K48 ubiquitination are specifically 
delivered to 26S proteasome for degradation.  p62 is the first reported, but also 
common mammalian ubiquitin-dependent cargo receptor.  Hereafter, I use p62 as a 
representative receptor to illustrate the selective nature of cargo receptors.  The 
ubiquitin-associated (UBA) domain, which mediates the interaction with the ubiquitin 
chain, is located at the C-terminal of p62.  The interaction between ubiquitin and 
UBA domain of cargo receptors are relatively weak, with a high micromolar range 
affinity (Long et al., 2010).  Oligomerization of p62 increases the avidity for cargo 
binding and is required for effective cargo degradation (Bjørkøy et al., 2005).  The 
dimerization and oligomerization of p62, mediated via UBA and its N-terminal Phox 
and Bem1 (PB1) domain, controls the activity of p62.  The UBA domain can form a 
stable dimer, which is a biologically inactive form (Long et al., 2010; Sims, Haririnia, 
Dickinson, Fushman, & Cohen, 2009).  This dimerization partially accounts for the 
low affinity of mono-ubiquitin binding.  The oligomerization driven by the PB-1 
domain aligns p62 proteins into a long helical form with the appearance of filaments.  
In the oligomerized forms, UBA domains will be in close proximity without forming 
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dimers and this array of UBA domains provides the selectivity for K63-linkage 
ubiquitin chains (Sims et al., 2009; Wurzer et al., 2015).  The binding affinity of p62 
and other SARs to LC3 is also low in micromolar range (Wirth et al., 2019; Zaffagnini 
& Martens, 2016).  Oligomerization of p62 renders high avidity for the LC3 cluster 
while the affinity of LIR to free LC3 is not changed.  Therefore, high avidity-driven 
interaction promotes the binding of the cargo-p62 complex to LC3-concentrated 
membrane (Wurzer et al., 2015). 
Various post-translational modifications are found to regulate the activities of 
ATG proteins.  As described above, the binding affinity of LIR:LC3 and UBA:ubiquitin 
is relatively low.  Phosphorylation of serine residues adjacent to the LIR motif 
provides a negatively charged environment, thus increasing the binding affinity to 
LC3 (see details in review (Zaffagnini & Martens, 2016)).  The binding affinity of 
UBA:ubiquitin can also be increased by phosphorylation of Ser403 within the UBA 
domain of p62 (Matsumoto, Wada, Okuno, Kurosawa, & Nukina, 2011).  This 
interaction is also reported to be enhanced by mono-ubiquitination of p62 (Peng et 
al., 2017).  Phosphorylation on LC3 is also observed and is reported to be essential 
for the fusion of autophagosome to the lysosome (Wilkinson et al., 2015).  
Acetylation of LC3 is reported to control the nuclear-cytoplasm shuttling (Huang et 
al., 2015).  
GSK3β Phosphorylation 
GSK3β Biology 
Glycogen synthase kinase-3 (GSK3) was first identified as one of the key 
enzymes that controls glycogen synthesis by phosphorylation and inhibition of its first 
reported substrate glycogen synthase (Embi, Rylatt, & Cohen, 1980).  There are 
more than a hundred proteins proposed to be GSK3 substrates, which define the 
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wide range of cellular processes that GSK3 is involved, including glucose 
metabolism and nutrient sensing, cell growth and development, and pathological 
situations, such as diabetes, cancers, neurodegenerative diseases, and psychiatric 
diseases.  GSK3 is ubiquitously expressed with two isoforms or paralogs of GSK3: 
GSK3α and GSK3β, encoded by two different genes.  They share a largely identical 
catalytic domain sequence while GSK3α has an additional glycine-rich region at the 
N-terminus as well as some C-terminal differences compared to GSK3β 
(Kaidanovich-Beilin & Woodgett, 2011).  Despite the similarity in the catalytic region 
of the two isoforms, they exhibit differences in terms of tissue-specific expression 
and some isoform-specific effects.  Deletion of GSK3β lead to embryonic lethality 
(Hoeflich et al., 2000), while GSK3α knockout mice are viable, but show increased 
sensitivity to glucose and insulin (MacAulay et al., 2007), indicating that these two 
isoforms are not interchangeable.   
Compared to most conventional kinases, GSK3 shows some special 
characteristics: (a) the phosphorylation of GSK3 requires pre-phosphorylation at 4 
amino acids C-terminal to GSK3 phosphorylation sites, termed as priming, by other 
kinases.  This pre-phosphorylation creates a binding site for GSK3, thus significantly 
enhancing GSK3 phosphorylation (Robertson, Hayes, & Sutherland, 2018).  Hence, 
the consensus GSK3 recognition sequence is Ser/Thr-X3 or 4-(P) Ser/Thr (X is any 
amino acid) and usually there are 1-3 Ser/Thr in a row with 3 or 4 amino acids in 
between.  GSK3 recognizes the C-terminal phosphorylated Ser/Thr and sequentially 
phosphorylates the substrate in the C- to N-terminus direction.  However, there are 
also reports for priming sites that are more than 4 amino acids adjacent to the GSK3 
target sites, at much further sites.  There are also examples that do not require 
priming (Robertson et al., 2018; Calum Sutherland, 2011).  (b) GSK3 is activated by 
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phosphorylation at Tyr 279 (GSK3α) or Tyr 216 (GSK3β) and it is phosphorylated 
during synthesis of GSK3 and constitutively remains phosphorylated (Cole, Frame, & 
Cohen, 2004).  (c) GSK3 is inhibited, instead of activated, upon stimulation such as 
insulin, growth factors and Wnt signaling, by phosphorylation at Ser 21 (GSK3α) or 
Ser 9 (GSK3β) (C Sutherland, Leighton, & Cohen, 1993).  This N-terminal Ser 
phosphorylation acts as a pseudo-primed site for GSK3 recognition and this 
inhibition can be overcome by competition of higher concentration of substrates 
(Frame, Cohen, & Biondi, 2001).  Since this phosphorylation is mimicking the primed 
substrates, this inhibition may not affect the phosphorylation of substrates that do not 
need priming. 
The GSK3β-Regulated Protein Degradation and β-catenin Destruction Complex 
GSK3 phosphorylation can alter the protein activity, protein-protein 
interaction, protein localization as well as protein half-life of its substrates.  There are 
different pools of GSK3β, incorporated into various protein complexes, responding to 
different stimuli and primed by specific kinases.  Phosphorylation by GSK3 can 
promote substrates for ubiquitination and degradation, but not all the proposed 
GSK3β substrates go through this process (Calum Sutherland, 2011).  In addition to 
the GSK3 phosphorylation, which generates a “phosphodegron” for their specific E3 
ligases, there are other components that help with E3 recognition and ubiquitination.  
Here, I use the well-studied GSK3β substrate, β-catenin, as an example to illustrate 
the classical degradation process after GSK3β phosphorylation. 
Wnt/ β-catenin signaling off mode.  As a transactivation coactivator, β-
catenin signaling controls Wnt responsive gene expression, whose abnormal 
regulation are indicated in diseases, such as cancers and metabolic diseases 
(MacDonald, Tamai, & He, 2009).  In the absence of Wnt signal, β-catenin is 
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continuously degraded in the cytoplasm with the help of its destruction complex.  
This complex is composed of two scaffold protein Axin and the adenomatous 
polyposis coli (APC), two kinases casein kinase 1 (CK1) and GSK3β.  The roles of 
these components are not fully clear.  In general, Axin interacts with β-catenin and 
two kinases and is the limiting step for the complex assembly.  It places β-catenin to 
close proximity of CK1 for priming, after which β-catenin can be recognized by 
GSK3β and thus phosphorylated.  Axin and APC can also be phosphorylated by 
CK1 and GSK3β, which enhance their interaction with β-catenin.  There are two 
ser/thr phosphatase involved in this destruction complex: PP1 and PP2A.  PP1 can 
dephosphorylate Axin and cause disassembly of this complex (Luo et al., 2007).  
PP2A dephosphorylates β-catenin, which can be protected by APC (Su et al., 2008).  
It should be noted that APC and PP2A are multifunction proteins whose roles are not 
fully understood.  The phosphorylated β-catenin can then be recognized by β-
transducin repeat containing proteins (β-TrCP), a subunit of β-catenin E3 ligase.  It is 
the SCF containing complex of RING E3 ligase family that helps with the β-catenin 
ubiquitination.  The SCF containing complex is composed of four proteins in the 
binding order of: RBX1, cullin-1, S-phase-kinase-associated-protein 1 (SKP1) and F-
box protein (Robertson et al., 2018).  β-TrCP is a phosphorylation-dependent F-box 
protein, which recognizes and binds to phosphorylated substrates.  Cullin-1 and 
SKP1 are two scaffold proteins which connect β-TrCP and RBX1, which transfers 
ubiquitin from E2 conjugating enzyme to substrate proteins.  β-TrCP usually targets 
proteins that contain a destruction motif or phosphodegron: D-S-G-X-X-S, of which 
the two serine are phosphorylated by GSK3β.  There are also examples of GSK3β/β-
TrCP substrates that only contain a minimal S/T-X-X-X- (P) S/T stretch.  The 
ubiquitinated β-catenin is then degraded by the proteasome.   
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Wnt/ β-catenin signaling on mode.  When Wnt proteins bind to 
transmembrane receptor Frizzled (Fz) and low-density lipoprotein receptor-related 
protein 6 (LRP6), with help of scaffold protein Dishevelled (Dvl), the Wnt-Fz-LRP5/6 
complex recruits Axin, which leads to LRP6 protein phosphorylation by GSK3β, 
resulting in the inhibition of β-catenin phosphorylation and dissociation of the 
destruction complex.  β-catenin is hence free and translocates into the nucleus, 
where it replaces the transcriptional repressor Groucho (Roose et al., 1998) from the 
Wnt responsive gene DNA-bound T cell factor/lymphoid enhancer factor (TCF/LEF) 
(Behrens et al., 1996; Molenaar et al., 1996).  This association of β-catenin with TCF 





CHAPTER 2: SELECTIVE AUTOPHAGY MAINTAINS THE ARYL HYDROCARBON 
RECEPTOR LEVELS IN HELA CELLS: A MECHANISM THAT IS DEPENDENT ON 
THE P23 CO-CHAPERONE 
 
Abstract 
The aryl hydrocarbon receptor (AHR) is an environmental sensing molecule 
which impacts diverse cellular functions such as immune responses, cell growth, 
respiratory function, and hematopoietic stem cell differentiation.  It is widely accepted 
that the degradation of AHR by 26S proteasome occurs after ligand activation.  
Recently, we discovered that HeLa cells can modulate the AHR levels via protein 
degradation without exogenous treatment with a ligand, and this degradation is 
particularly apparent when the p23 content is down-regulated.  Inhibition of 
autophagy by a chemical agent (such as chloroquine, bafilomycin A1, or 3-
methyladenine) increases the AHR protein levels in HeLa cells whereas activation of 
autophagy by short-term nutrition deprivation reduces its levels.  Treatment with 
chloroquine retards the degradation of AHR and triggers physical interaction 
between AHR and LC3B.  Knockdown of LC3B suppresses the chloroquine-
mediated increase of AHR.  Down-regulation of p23 promotes AHR degradation via 
autophagy with no change of the autophagy-related gene expression.  Although 
most data in this study were derived from HeLa cells, human lung (A549), liver 
(Hep3B), and breast (T-47D and MDA-MB-468) cancer cells also exhibit AHR levels 
sensitive to chloroquine treatment and AHR–p62/LC3 interactions.  Here we provide 
evidence supporting that AHR undergoes the p62/LC3-mediated selective autophagy 




The aryl hydrocarbon receptor (AHR) is originally recognized as a 
transcription factor in response to environmental toxicants such as dioxins and 
polycyclic aromatic hydrocarbons (Poland et al., 1976).  Since then, more roles of 
AHR such as its involvement in organ development (Schmidt, Su, Reddy, Simon, & 
Bradfield, 1996), immune responses (Quintana et al., 2008; Ye et al., 2017), nervous 
system homeostasis (Juricek & Coumoul, 2018), and carcinogenesis (Kolluri et al., 
2017; Opitz et al., 2011) have been reported.  Not surprisingly, AHR has become a 
promising target for the treatment of diseases such as autoimmune diseases, 
inflammation, and cancers.  However, the AHR function is often ligand-, cell context-, 
and tissue-specific, confounding the feasibility of targeting AHR for rational drug 
design.  Understanding the basic biology of AHR will provide much-needed 
information for effective modulation of the AHR function. 
AHR resides in the cytoplasm as a complex with HSP90, XAP2, and p23.  
The p23 co-chaperone is in a variety of HSP90 client protein complexes (Holt et al., 
1999; Johnson & Toft, 1995; S. C. Nair et al., 1996; Roland & J., 1999).  It has been 
reported that p23 stabilizes the ATP-induced conformation of the HSP90-AHR 
complex (Cox & Miller  3rd, 2004; Young, Moarefi, & Ulrich Hartl, 2001).  AHR 
function can also be enhanced by p23 in vitro (Jinyun Chen, Yakkundi, & Chan, 
2019; Cox & Miller  3rd, 2004; P. M. Nguyen et al., 2012a; Shetty et al., 2003), but 
surprisingly this enhancement is not observed in the p23-null mouse embryo (C. 
Flaveny et al., 2009), possibly due to yet unidentified compensatory mechanisms.  
The effect of p23 on AHR is largely uncharacterized at present. 
Autophagy is essential in maintaining cell homeostasis by delivering cytosolic 
cargos to lysosomes for degradation. There are three types of autophagy: 
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macroautophagy which involves the formation of autophagosome, followed by its 
fusion with lysosome.  Microautophagy, which involves substrates that are directly 
sequestered via lysosomal invagination; and lastly, chaperone-mediated autophagy, 
a process that involves the HSC70-mediated delivery of client proteins into lysosome 
via interaction with LAMP-2A (for general review, see (Mizushima, Levine, Cuervo, & 
Klionsky, 2008)).  Although macroautophagy is generally known to deliver bulk 
cargos to lysosomes in a non-selective manner, it can also be selective in delivering 
cargo proteins for lysosomal degradation.  Recognition of client proteins by cargo 
receptors (such as p62) provides the selectivity of macroautophagy.  This 
recognition, in most cases, is mediated through the ubiquitination of client proteins. 
Different linkages of ubiquitin destine the ubiquitinated proteins to different 
degradation pathways; for example, K63 ubiquitination is usually recognized by 
cargo receptors to undergo lysosomal degradation whereas proteins with K48 
ubiquitination are specifically delivered to 26S proteasome for degradation 
(Korolchuk, Menzies, & Rubinsztein, 2010).  After K63 ubiquitination of a client 
protein, LC3B-II, a phosphatidylethanolamine-conjugated, membrane-bound form of 
cleaved LC3B-I (Y. K. Lee & Lee, 2016), forms the autophagosome with the client 
protein–cargo receptor complex, leading to lysosomal degradation of the client 
protein (Y. K. Lee & Lee, 2016; Zaffagnini & Martens, 2016). 
Upon binding of a ligand, AHR translocates into the nucleus and activates 
gene transcription.  The liganded AHR is subsequently degraded by the ubiquitin–
proteasome system to limit its transactivation function (Q. Ma & Baldwin, 2000).  
However, how AHR is regulated in the absence of exogenous ligand treatment 
remained unclear.  We previously discovered that down-regulation of just half of the 
p23 cellular content is sufficient to cause a lower cellular content of AHR in various 
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cancer and untransformed cell types in vitro (Jinyun Chen et al., 2019; P. M. Nguyen 
et al., 2012a; Pappas et al., 2018).  AHR is degraded significantly faster in the p23 
knockdown Hepa1c1c7 cells; however, inhibition of proteasome activity by MG132 
cannot restore the AHR protein levels, suggesting that AHR is not degraded by the 
26S proteasome when p23 is down-regulated (P. M. Nguyen et al., 2012a).  
Treatment with MG132, surprisingly, decreases the AHR protein levels in both wild 
type and p23 knockdown Hepa1c1c7 cells, suggesting that mechanisms in 
degrading the unliganded AHR protein could be enhanced by proteasomal inhibition.  
It has been reported that crosstalk occurs between the ubiquitin–proteasome system 
(UPS) and autophagy (Korolchuk, Mansilla, Menzies, & Rubinsztein, 2009a; Nam, 
Han, Devkota, & Lee, 2017).  Blockade of UPS leads to protein aggregation, which in 
turn triggers the autophagy-mediated protein degradation (Zhu, Dunner, & 
McConkey, 2010).  In addition, reduced amino acids in cells as a consequence of 
MG132 treatment can activate autophagy (Harhouri et al., 2017).  Thus, we explored 
whether the autophagy-lysosomal system is responsible for the degradation of AHR 
without exogenous ligand treatment.  Here we provide evidence to support that the 
basal AHR protein levels in HeLa cells are controlled by selective autophagy.  
Knockdown of p23 reduces AHR protein levels by promoting the K63-linked 
ubiquitination of AHR, followed by the p62/LC3-mediated AHR degradation. 
Results 
Autophagy Activity in Wild Type and p23 Stable Knockdown HeLa Cells 
Governs the Levels of AHR 
We previously observed that suppression of the AHR levels after down-
regulation of p23 in Hepa1c1c7 mouse hepatoma cells was caused by increased 
AHR degradation, which could not be reversed by the treatment of a proteasome 
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inhibitor MG132 (P. M. Nguyen et al., 2012b).  In this study, we observed that 
MG132 similarly reduced the AHR content in wild type and p23 knockdown (human 
cervical) HeLa cells in a statistically significant manner (Figure 2.1A).  We then 
explored whether this AHR degradation could be mediated through autophagy-
mediated lysosomal degradation.  We treated the HeLa cells with an autophagy 
inhibitor CQ at 20 or 40 μM for six hours.  We observed that the AHR protein levels 
in both wild type and p23 stable knockdown HeLa cells were increased in the 
presence of 40 μM CQ (Figure 2.1B, C).  The cellular AHR protein level in p23 stable 
knockdown HeLa cells was about 54% when compared to that of wild type HeLa 
cells (Figure 2.1C, “WT” versus “NT”).  However, the AHR levels in p23 stable 
knockdown cells became even higher than the levels in wild type cells after 
treatment with 40 μM CQ for six hours, suggesting that mechanism of the p23-
mediated AHR degradation can be reversed by CQ.  Next, we performed the 
cycloheximide experiment to examine whether degradation of AHR is mediated 
through autophagy.  Basically, when protein synthesis in HeLa cells is blocked by 
cycloheximide, any reduction of the AHR content is the consequence of protein 
degradation.  If this degradation is mediated through autophagy, CQ should, in 
principle, reverse the AHR reduction in the presence of cycloheximide.  Indeed, we 
observed that degradation of the AHR protein in p23 stable knockdown and wild type 
HeLa cells was inhibited in the presence of CQ (Figure 2.1D, E, “CHX” versus 
“CHX+CQ”).  Two other autophagy inhibitors, namely Baf A1 and 3MA, also 
increased the AHR protein levels in p23 stable knockdown HeLa cells (Figure 2.1F, 
G).  However, only 5 mM 3MA, but not 6 nM Baf A1, increased the AHR levels in 
wild type HeLa cells.  An autophagy inducer metformin decreased the AHR protein 
levels in p23 knockdown but not in wild type HeLa cells at 1 mM concentration 
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(Figure 2.1H).  We cannot rule out the possibility that a higher concentration of Baf 
A1 and metformin is necessary for eliciting changes of the AHR levels in wild type 
HeLa cells.  Nonetheless, these data supported that the basal AHR undergoes the 
autophagy-mediated degradation in HeLa cells and this degradation is more 
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Figure 2.1.  Using an autophagy inhibitor or activator to reveal that the aryl 
hydrocarbon receptor (AHR) undergoes autophagy in wild type (WT) and p23 stable 
knockdown (p23KD) HeLa cells 
(Figure 2.1 Continued) 
 
                                                               
 
                                                .  (A) MG132 (10 μM for 6 h) decreased AHR protein 
levels more in HeLa cells transiently transfected with p23 shRNA (2.5 μg for 48 h) 
than in WT HeLa cells.  EndoFectin transfection reagent (2:1) was used.  The below 
images are representative of the replicate data (means ± SD, n = 4).  Conditions with 
no MG132 treatment were arbitrarily set as one (with no error bar) for data 
normalization.  Multiple t-tests corrected with the Hold-Sidak method for multiple 
comparisons were performed to determine statistical significance.  (B) WT and (C) 
p23KD HeLa cells were treated with 20 μM or 40 μM chloroquine (CQ) dissolved in 
water for 6 h.  Western analysis results showed a higher increase of AHR in p23KD 
than in WT HeLa cells after 40 µM CQ treatment.  For (B, C), the below images are 
representative of the replicate data of one experiment (means ± SD, n = 3).  
Conditions with no addition as no treatment (NT) were arbitrarily set as one for 
comparison.  This experiment was repeated once with similar results.  One-way 
ANOVA with Sidak’s multiple comparisons test was performed to determine 
statistical significance.  (D) WT and (E) p23KD HeLa cells were treated with 40 













































































(Figure 2.1 Continued) 
 
12 h (6 h pre-treatment and then co-treated with CHX for another 6 h).  The 
degradation of AHR in both cell lines was inhibited by CQ.  For (D, E), the below  
images are representative of the replicate data (means ± SD, n = 3).  Conditions with 
no addition as no treatment (NT) were arbitrarily set as one (with no error bar) for 
data normalization.  Multiple t-tests corrected with the Hold-Sidak method for multiple 
comparisons were performed to determine statistical significance.  (F) Treatment 
with 6 nM Bafilomycin A1 (Baf A1) dissolved in DMSO for 3 h increased AHR protein 
levels only in p23KD cells but not WT HeLa cells.  (G) Treatment with 5 mM 3-
methyladenine (3MA) dissolved in DMEM for 24 h increased AHR protein levels in 
WT and p23KD HeLa cells.  For (F, G), the below images are representative of the 
replicate data (means ± SD, n = 3 for (F), n = 4 for (G)).  Conditions with DMSO 
treatment and no addition as no treatment (NT) of WT and p23KD were arbitrarily set 
as one (with no error bar) for data normalization.  Multiple t-tests corrected with the 
Hold-Sidak method for multiple comparisons were performed to determine statistical 
significance.  (H) Treatment with 1 mM metformin (Met) for 4 h decreased AHR 
protein levels in p23KD HeLa cells but not in WT HeLa cells. The above images 
represent the replicate data of one experiment (means ± SD, n = 3).  Conditions with 
no treatment (NT) were arbitrarily set as one for comparison.  This experiment was 
repeated once with similar results.  Multiple t-tests corrected with the Hold-Sidak 
method for multiple comparisons were performed to determine statistical 
significance.  For (A–H), each Western lane contained 30 μg of whole-cell lysate.  
Data in (D, F) were normalized by β-actin (as shown) whereas the rest of the data 
were normalized by total protein stain. 
 
Short-Term Nutrient Deprivation Triggers Degradation of AHR in HeLa Cells 
When Either p23 or HSP90 Is Down-Regulated 
To further investigate whether autophagy is involved in the degradation of 
AHR, we treated the HeLa cells with HBSS to mimic nutrient deprivation, which is 
known to cause autophagy.  We observed that the AHR protein levels were reduced 
after 15 min of HBSS treatment and were then gradually increased up to four hours 
in p23 knockdown HeLa cells (Figure 2.2A).  In contrast, the AHR protein levels of 
wild type HeLa cells were steadily increased up to four hours of HBSS treatment.  
Pre-treatment with CQ hampered the reduction of AHR in p23 knockdown HeLa 
cells, suggesting that this decrease of AHR protein levels is caused by autophagy 
(Figure 2.2B).  We hypothesized that some compensatory mechanism may be 
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involved in protecting AHR from degradation under nutrition deprivation in HeLa 
cells.  Given that HSP90 stabilizes the cytosolic AHR complex, we examined 
whether HSP90 would protect AHR from degradation caused by nutrient deprivation 
in HeLa cells.  We down-regulated HSP90 in HeLa cells with shRNA via lentiviral 
infection and then treated these HSP90 knockdown cells with HBSS.  We observed 
that these cells exhibited similar characteristics as the p23 knockdown cells but not 
as the wild type cells, suggesting that this decrease of AHR could be protected by 
HSP90 (Figure 2.2A).  qPCR data showed that 4 h HBSS treatment significantly 
increased the amount of the ahr message in wild type HeLa cells (Figure 2.2C).  Co-
treatment with a transcription inhibitor actinomycin D with HBSS in wild type HeLa 
cells abolished the increase of AHR protein levels caused by HBSS (Figure 2.2D).  
Collectively, these data supported that although nutrient deprivation caused 
degradation of AHR via autophagy initially, it increased the synthesis of the AHR 




























































Figure 2.2.  Short-term nutrient deprivation triggers the degradation of AHR in HeLa 
cells when either p23 or HSP90 is down-regulated 
(Figure 2.2 Continued) 
 
 
                                                                          .  (A) Zero to four hours’ treatment 
of HBSS (nutrient deprivation) in wild type (WT), p23 stable knockdown (p23KD), 
and HSP90 stable knockdown (HSP90KD) HeLa cells.  Fifteen minutes of HBSS 
treatment decreased AHR protein levels in p23KD and HSP90 HeLa cells but not in 
WT HeLa cells.  Longer nutrient deprivation of up to 4 h increased AHR protein 
levels in all three cell lines.  The graph represents replicate data of means ± SD 
(upper error bars shown), n = 3 for all, except n = 4 for HSP90KD data from 0 to 1 h.  
Zero timepoints in each cell line were arbitrarily set as one for comparison.  Data 
were analyzed by unpaired two-tailed t-test for comparisons between zero and 15 
min timepoints in each individual cell line (significant data points marked with # 
symbol).  Data were analyzed by two-way ANOVA (mixed-model) analysis corrected 
with the Dunnett test for multiple comparisons to determine the statistical 
significance between WT and p23KD or WT and HSP90 KD at each time point 
(significant data points marked with * symbol).  WT HeLa data were set as a control 
group at each timepoint for comparison.  The images above represent the replicate 
data.  Note that the timepoints are intentionally presented not in chronological order  
 















































(Figure 2.2 Continued) 
 
to preserve the integrity of the original immunoblots.  (B) A 40 μM amount of CQ pre-
treatment for 6 h blocked the AHR decrease in p23KD HeLa cells treated with HBSS  
for 0–1 h.  Zero time points in each condition were arbitrarily set as one for 
comparison.  The graph represents replicate data of means ± SD (upper error bars 
shown), n = 3.  Data were analyzed by multiple t-tests corrected with the Hold-Sidak 
method for multiple comparisons to determine the statistical significance. The 
images above represent the replicate data.  (C) A 4 h HBSS treatment significantly 
increased the ahr message levels in WT HeLa cells.  The graph represents replicate 
data of means ± SD, n = 3 of one experiment.  This experiment was repeated once 
with similar results.  Data were analyzed by unpaired t-test to determine statistical 
significance.  (D) Treatment with 5 μg/mL of actinomycin D (ActD) for 4 h abolished 
the increase of AHR protein levels induced by HBSS (nutrient deprivation) in WT 
HeLa cells.  The graph represents replicate data of means ± SD, n = 3 of one 
experiment.  This experiment was repeated once with similar results.  Data were 
analyzed by one-way ANOVA with Tukey’s multiple comparisons test to determine 
statistical significance.  For A to D, each Western lane contained 30 μg of whole-cell 
lysate.  The intensity of all Western bands was normalized by total protein stain. 
 
Down-Regulation of p23 in HeLa Cells Exhibits Higher Autophagic Flux 
Next, we examined whether knockdown of p23 in HeLa cells stimulates 
autophagy, which in turn accelerates the degradation of the AHR protein.  It is well 
accepted that LC3B-II plays a key role in macroautophagy (Jiang & Mizushima, 
2015).  Its turnover can be used as a marker for autophagic flux, which reflects the 
frequency of events from autophagosome formation to substrate degradation during 
macroautophagy.  In other words, the amount of LC3B-II in the autophagosomes and 
lysosomes is directly proportional to the autophagy activity, which is referred to as 
the autophagic flux.  We measured the LC3B-II protein levels and observed that the 
LC3B-II band was more intense in p23 knockdown HeLa cells than in wild type cells 
(Figure 2.3A, “WT, 0 h” versus “p23KD, 0 h”).  Since CQ inhibits the LC3B-II 
degradation by acidic proteases in the lysosomes, the LC3B-II content can be more 
easily detected in the presence of CQ.  The autophagic flux, which was determined 
by the slope of LC3B-II levels over time with CQ treatment, was also higher in p23  
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Figure 2.3.  Down-regulation of p23 in HeLa cells exhibits higher autophagic flux                                                                                                                        .  
(A) Western blot analysis showing that p23 stable knockdown (p23KD) HeLa cells 
have higher basal LC3B-II protein levels as well as higher autophagic flux than wild 
type (WT) HeLa cells in the presence of 40 μM CQ.  The graph in A represents 
replicate data of means ± SD (upper error bars shown), n = 3 of one experiment.  
This experiment was repeated once with similar results.  Data were analyzed by 
multiple t-tests corrected with the Hold-Sidak method for multiple comparisons to 
determine the statistical significance.  The above images are representative of the 
replicate data.  Note that the hour under WT is intentionally presented as “6 h, 0 h, 
12 h, 24 h” to preserve the integrity of the original immunoblot.  Each Western lane 
contained 30 μg of whole-cell lysate.  The intensity of Western bands was 
normalized by the total protein stain.  (B) Qiagen RT2 Profiler PCR array analysis of 
84 autophagy-related gene expression showing that knockdown of p23 did not alter 
the autophagy-related gene transcription when compared to wild type (WT).  The 
scatter plot compares WT HeLa (x-axis) to p23 knockdown (p23KD) HeLa (y-axis) 
with a fold regulation setting as 2. 



































































knockdown than in wild type cells (Figure 2.3A), suggesting that down-regulation of 
p23 in HeLa cells sensitized macroautophagy.  Next, we performed a PCR array to 
test whether knockdown of p23 would change the expression of autophagy-related 
genes.  The expression of 84 autophagy-related genes (Table 5 in APPENDIX C) 
was measured using the Qiagen RT2 Profiler PCR array kit.  However, the gene 
expression related to autophagy was not significantly different between wild type and 
p23 knockdown HeLa cells (Figure 2.3B), suggesting that the down-regulation of p23 
leads to higher autophagic activity without affecting the autophagy-related gene 
expression. 
AHR Undergoes Selective Autophagy in p23 Knockdown and Wild Type HeLa 
Cells 
Thus far, our data suggested possibly an LC3B-II-dependent lysosomal 
degradation of AHR in HeLa cells—this type of degradation has been described as 
selective (macro)autophagy.  The selectivity of autophagy is mainly conveyed by the 
specific binding of cargo proteins to cargo receptors (e.g., p62) and the binding of 
LC3B-II to the cargo protein–cargo receptor complex (Danieli & Martens, 2018).  We 
first examined the role of LC3B in the degradation of AHR in HeLa cells.  Stable 
knockdown of LC3B gene (MAP1LC3B) in HeLa cells to 12.5% of the wild type LCB-I 
content showed an increase of the AHR protein levels when compared to the wild 
type HeLa cells (Figure 2.4A, left graph).  In addition, knockdown of LC3B led to less 
LC3B-II formed from LC3B-I lipidation and suppressed the CQ effect on AHR, 
consistent with our suspicion that CQ might block the LC3B-mediated degradation of 
the AHR protein (Figure 2.4A,B, right graphs).  Next, we transiently down-regulated 
40% of the LC3B-I content in p23 knockdown HeLa cells and observed a higher 
increase of AHR when compared to the LC3B knockdown HeLa cells (Figure 2.4A,B, 
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left graphs).  The response of AHR to CQ treatment was also significantly 
suppressed by the LC3B knockdown (Figure 2.4B, right graph).  Next, we examined 
whether AHR physically interacts with LC3B-II, leading to selective autophagy of the 
AHR protein.  We observed that LC3B-II interacted with AHR in our 
coimmunoprecipitation experiment and this interaction can be significantly enhanced 
by CQ in both wild type and p23 knockdown HeLa cells (Figure 2.4C).  There was 
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Figure 2.4.  AHR interacts with LC3B-II and p62 in p23 stable knockdown (p23KD) 
and wild type (WT) HeLa cells 
(Figure 2.4 Continued) 
 
                               
                                           .  (A) Stable knockdown of LC3B in HeLa cells 
increased AHR protein levels and reduced the extent of the CQ-mediated increase of 
AHR.  The images above show LC3B-I, LC3B-II, and AHR protein levels in WT and 
LC3B stable knockdown (KD) HeLa cells with or without treatment with 40 μM CQ for 
6 h of triplicate samples.  The graphs represent replicate data of means ± SD of one 
experiment, n = 3.  WT (left graph) and NT (right graph) were arbitrarily set as 1 for 
data normalization.  This experiment was repeated once with similar results.  Data of 
the left graph were analyzed by multiple t-tests corrected with the Hold-Sidak method 
for multiple comparisons to determine statistical significance whereas data of the 
right graph were analyzed by one-way ANOVA with Sidak’s multiple comparisons 
test to determine statistical significance.  (B) Transient knockdown of LC3B in p23 
stable knockdown (p23KD) HeLa cells showed a higher increase of AHR protein 
levels when compared to that in WT HeLa cells (see A) and reduced the extent of 
CQ-mediated increase of AHR.  The graphs represent replicate data of means ± SD 
of one experiment, n = 3. p23KD (left graph), and no addition as no treatment (NT, 
right graph) were arbitrarily set as 1 for data normalization.  This experiment was 
repeated once with similar results.  Data of the left graph were analyzed by multiple 
t-tests corrected with the Hold-Sidak method for multiple comparisons to determine 
statistical significance whereas data of the right graph were analyzed by one-way 
ANOVA with Sidak’s multiple comparisons test to determine statistical significance.  
(C) LC3B-II was co-immunoprecipitated by AHR polyclonal antibody SA210 in both 
cell lines after treatment with 40 μM CQ for 6 h.  Data were presented from three 
independent experiments as means ± SD, n = 3.  WT HeLa NT group was arbitrarily 
set as one for comparison (no error bar).  Data were analyzed by multiple t-tests 
corrected with the Hold-Sidak method for multiple comparisons to determine 
statistical significance.  The images below are representative of the replicate data. 
(D) p62 was co-immunoprecipitated by AHR monoclonal antibody A-3x after 
treatment with 40 μM CQ for 6 h in WT HeLa cells.  This experiment was repeated 
once with similar results.  For A-B, each Western lane contained 30 μg of whole-cell 
lysate or the whole immunoprecipitation content from 1 to 2 mg of whole-cell lysate 
starting material (C and D).  Data were normalized by total protein stain. 
 

























































Proximity ligation assay was performed to confirm whether AHR would 
physically interact with LC3B and p62 in HeLa cells in situ.  We observed that AHR 
interacted with LC3B (Figure 2.5A) and p62 (Figure 2.5B) in both wild type and p23 
knockdown HeLa cells, whereas negative control groups without the addition of 
antibodies against the interaction partners did not show signals.  There were more 
AHR–LC3B and AHR–p62 interactions in p23 knockdown than in wild type HeLa 
cells (Figure 2.5A,B).  We expected that the signal of the LC3B-AHR interaction 
should be enhanced in the presence of CQ since LC3B-II can be accumulated when 
acidic proteases in the lysosomes are inhibited by CQ.  Indeed, treatment with CQ 
enhanced the AHR–LC3B interaction significantly in p23 knockdown HeLa cells but 
not in WT HeLa cells (Figure 2.5A).  Macroautophagy (or autophagy) can selectively 
degrade K63-ubiquitinated target proteins (Mukhopadhyay & Riezman, 2007).  Given 
that we observed an interaction between AHR and p62, which is a known ubiquitin-
binding cargo receptor, we examined the ubiquitination status of AHR in wild type 
and p23 knockdown HeLa cells.  We observed that AHR was K63-ubiquitinated in 
both cell lines without exogenous ligand treatment and significantly more K63-
ubiquitination was detected in p23 knockdown HeLa cells (Figure 2.6A).  Both cell 
lines showed minimal levels of K48-ubiquitinated AHR protein levels (Figure 2.6B, 
“KD NT” and “NT” lanes of image).  Co-treatment with an AHR ligand 3MC in the 
presence of a proteasome inhibitor MG132 showed a more intense K48-
ubiquitinated AHR protein (Figure 2.6B), which exhibited a pattern that was different 
from the K63-ubiquitination of AHR as shown in Figure 2.6A.  Collectively, these data 
supported that the basal AHR protein undergoes K63-ubiquitination (but not K48-
ubiquitination) in HeLa cells and this K63-ubiquitination is more apparent when p23 
is down-regulated.  AHR undergoes p62/LC3-mediated selective autophagy via K63-
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Figure 2.5.  Proximity ligation assay results showing that AHR interacts with LC3B 
and p62 in wild type (WT) and p23 stable knockdown (p23KD) HeLa cells 
ubiquitination in the absence of ligand treatment.  Down-regulation of p23 promotes 
this degradation process, leading to a decrease in the basal AHR protein levels. 
 
 
                                                                                                            .  (A) More 
AHR–LC3B interaction was detected in p23KD than in WT HeLa cells (NT images) 
and treatment with 40 μM CQ for 6 h increased the interaction (CQ versus NT 
images).  (B) p23KD cells showed more AHR–p62 interaction than in WT HeLa cells 
(NT images).  The graphs represent replicate data of means ± SD of one 
experiment, n=3.  This experiment was repeated twice with similar results.  Image J 
software was used to measure signal dots (red channel) and cell numbers (nucleus 
numbers in the blue channel) in each of the whole images captured (signals and 
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Figure 2.6.  AHR undergoes K63 ubiquitination in p23 stable knockdown (p23KD) 
and wild type (WT) HeLa cells 
(Figure 2.5 Continued) 
 
two-way ANOVA with Tukey’s multiple comparisons test (A) and unpaired t-test (B).  
The images are representative of the replicate data with a scale bar at the right 
bottom of each image.  NC, negative control (cells incubated without antibodies 




                                           .  (A) Immunoprecipitation of AHR by AHR polyclonal 
antibody SA210, followed by K63-TUBE Far-western analysis showing more K63-
ubiquitinated AHR in p23KD than in WT HeLa cells.  The graph represents replicate 
data (means ± SD, n = 6).  The mean of WT HeLa was arbitrarily set as one for 
comparison.  Data were analyzed by unpaired t-test to determine statistical 
significance.  The images above are representative of the replicate data.  (B) K48-
TUBE was used for Far-western analysis showing minimal K48-ubiquitination of AHR 
in WT and p23KD HeLa cells.  Treatment with 3MC (1 μM) and MG132 (10 μM) for 2 
h showed accumulation of K48-ubiquitinated AHR.  The pattern of K48-ubiquitinated 
AHR was different from K63-ubiquitinated AHR.  The graph represents replicate data 
(means ± SD, n = 3).  One WT HeLa NT value was arbitrarily set as one for 
comparison.  Data were analyzed by one-way ANOVA with Tukey’s multiple 
comparisons test to determine statistical significance.  The images above are 
representative of the replicate data.  “WT NT” stands for wild-type HeLa cells with no 
treatment whereas “KD NT” stands for p23 knockdown HeLa cells with no treatment. 
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AHR Is Degraded Via Autophagy in Human Lung, Liver, and Breast Cancer Cell 
Lines 
Next, we examined whether the p62/LC3-mediated autophagy of AHR in 
HeLa cells can be observed in other cell types.  We observed that the AHR protein 
levels were significantly increased to about 1.5- to 1.7-fold in the presence of 40 µM 
CQ for six hours in a variety of cancer cell types—namely liver cancer cell line 
Hep3B, lung cancer cell line A549, and two breast cancer cell lines T-47D and MDA-
MB-468.  These results showed that similar to HeLa cells, AHR in these cells is likely 
degraded via autophagy in the absence of ligand treatment (Figure 2.7A).  Results 
from proximity ligation assay confirmed that AHR interacted with LC3B in the 
presence or absence of CQ (Figure 2.7B).  In addition, the interaction between AHR 
and p62 was detected in all four cell types (Figure 2.7C). 
 
 







































Figure 2.7.  AHR is degraded via autophagy in human lung, liver, and breast cancer 
cell lines 
(Figure 2.7 Continued) 
 
                                                                                                                                                        
             .  (A) Treatment with 40 μM CQ dissolved in water for 6 h increased AHR 
protein levels in A549, Hep3B, T-47D, and MDA-MB-468 cells (means ± SD; n = 3 of 
one experiment, except for n = 5 for Hep3B).  This experiment was repeated once 
with similar results.  Each Western lane contained 30 μg of whole-cell lysate.  Data 
are normalized by the total protein stain.  NT, no addition as no treatment.  An 
unpaired t-test was used to determine statistical significance.  The images below are 
representative of the replicate data.  Proximity ligation assay results showing that 
AHR interacted with (B) LC3B and (C) p62 in all four cell lines.  All images are 
representative of the replicate data of three independent experiments.  Each image 
contains a scale bar at the right bottom.  NC, negative control (cells incubated 
without primary antibodies against interaction partners); NT, no addition as no 
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Figure 2.8.  Activation of chaperone-mediated autophagy does not degrade AHR in 
HeLa cells 
Chaperone-Mediated Autophagy Is Unlikely Involved in the Degradation of 
AHR in HeLa Cells 
Next, we explored whether another selective autophagic pathway, namely 
chaperone-mediated autophagy, could degrade AHR in HeLa cells.  This type of 
autophagy requires interaction with the lysosomal membrane-bound protein 
LAMP2A for the internalization of cargo protein into lysosomes for degradation.  
When HeLa cells were treated with 100 µM 6-AN, a chaperone-mediated autophagy 
activator, for 24 h, the AHR levels were not significantly altered (Figure 2.8).  
However, the LAMP2 immunoblot signal, which was detected using an antibody that 
recognizes both LAMP2A and LAMP2B, was significantly reduced after the 6-AN 
treatment.  Collectively, we were not able to show any involvement of chaperone-
mediated autophagy in the degradation of AHR in HeLa cells. 
 
                                                                                                                                         
                .  Wild type (WT) HeLa cells were treated with a chaperone-mediated 
autophagy activator 6-aminonicotinamide (6-AN, 100 μM) for 24 h.  Treatment with 
6-AN did not change AHR protein levels (bottom left graph) but reduced LAMP2 
levels (bottom right graph).  Images above are representative of triplicate samples in 
one experiment and this experiment was repeated once with similar results.  Each  
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(Figure 2.8 Continued) 
 
Western lane contained 30 μg of whole-cell lysate.  Data are normalized by the total 
protein stain.  The plots represent means ± SD, n = 3. An unpaired t-test was used to 
determine statistical significance. 
 
Discussion 
We used HeLa cells for this study since HeLa cells were one of the human 
cell lines, we first tried that exhibit apparent p23-dependent degradation of AHR (P. 
M. Nguyen et al., 2012a).  HeLa cells increase the AHR content after the treatment 
with an autophagy inhibitor such as CQ, Baf A1, or 3MA.  CQ and Baf A1 suppress 
the acidification of lysosomes and the fusion of autophagosomes with lysosomes 
(Steinman, Mellman, Muller, & Cohn, 1983) whereas 3MA inhibits autophagosome 
formation via inhibition of class III PI3K at the early stages of autophagy (Wu et al., 
2010).  The basal AHR protein can be ubiquitinated via K63-linkage and then 
degraded in LC3B-dependent autophagy.  p62 likely acts as the cargo receptor of 
AHR to undergo autophagy since we can detect the AHR–p62 interaction by co-
immunoprecipitation study and proximity ligation assay.  Similarly, it has been 
reported that Dvl is degraded via the p62/LC3-mediated autophagy upon Wnt ligand 
activation (Gao et al., 2010).  In addition, TH9 cell transcription factor is selectively 
degraded via the p62/LC3 pathway in an Atg5-dependent manner (Rivera Vargas et 
al., 2017).  Selectivity is largely conferred by the ubiquitination architectures of the 
client proteins and the preference of the cargo receptor to certain ubiquitin chains 
and cargoes.  The chain formation including chain length, mixed, or branched chains 
may attach more information for the ubiquitin code.  Post-translational modification of 
both the adaptors and the ubiquitin chains also adds more layers of regulation (Kwon 
& Ciechanover, 2017; Ohtake & Tsuchiya, 2017; Zaffagnini & Martens, 2016).  
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Characterization of the ubiquitination machinery and the nature of the AHR–p62 
interactions would provide a better picture of how AHR undergoes the LC3B-
mediated autophagy. 
As a co-chaperone of HSP90, p23 has been reported to stabilize HSP90 
confirmation and assist AHR activation (A Kazlauskas et al., 1999).  The expression 
of p23 is ubiquitous; however, there is limited, if any, information regarding the 
regulation of p23 gene expression.  Additionally, there is no evidence showing that 
the p23 levels can be altered in the presence of an AHR ligand.  Although p23 
stabilizes AHR from degradation in cell lines (Jinyun Chen et al., 2019; P. M. Nguyen 
et al., 2012a), there is limited information on how p23 maintains the AHR protein 
levels in the absence of ligand treatment.  In this study, the increase of the AHR 
protein levels in HeLa cells by CQ is higher when p23 is down-regulated, consistent 
with the notion that CQ inhibits autophagy, which is responsible for the p23-
dependent AHR degradation.  Proteins with a glutamine-rich region (such as AHR) 
are known to be more prone to aggregation, and these proteins can be degraded by 
autophagy (Ravikumar, Duden, & Rubinsztein, 2002).  Since p62/LC3 is involved in 
autophagic degradation of misfolded proteins (Pankiv et al., 2007), reduction of the 
p23 content in HeLa cells may allow AHR to be more prone to aggregation and 
become accessible for ubiquitination.  This hypothesis is supported by our findings 
that the response of AHR to autophagy inhibition, activation, and LC3B knockdown 
are more pronounced in HeLa cells when p23 is down-regulated.  Moreover, the 
interaction between AHR and p62 (or LC3B) is more apparent in p23 knockdown 
HeLa cells.  The autophagy-related gene expression, however, did not show any 
significant difference between wild type and p23 knockdown HeLa cells.  Although 
we are not aware of any report showing the correlation between p23 and autophagy 
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activity, the basal LC3B-II levels and the autophagic flux are unambiguously higher 
when p23 is down-regulated in HeLa cells.  Collectively, we concluded that the 
down-regulation of p23 promotes autophagy to selectively degrade AHR without 
altering the expression of any autophagy-related gene.  Importantly, the down-
regulation of p23 in HeLa cells causes more K63-ubiquitination of AHR in the 
absence of ligand treatment, revealing that reduction of the cellular p23 content to 
about 50% in HeLa cells is sufficient to promote the K63-ubiquitination of AHR, 
leading to the p62/LC3B-mediated selective autophagy. 
Interestingly, it has been reported that HIF-1α—another member of the AHR 
PAS protein family—can be K63-ubiquitinated, and this ubiquitination leads to 
chaperone-mediated autophagy of HIF-1α during serum deprivation (Ferreira, 
Soares, Ramalho, Pereira, & Girao, 2015).  HIF-1α is constantly degraded by 26S 
proteasome under normoxic conditions.  In the absence of serum, the KFERQ-like 
motif of HIF-1α interacts with HSC70; K63-ubiquitination of HIF-1α apparently 
causes the interaction between HIF-1α and the lysosomal membrane-bound LAMP-
2A—a necessity for internalization of HIF-1α into lysosomes for degradation.  We 
examined the possible role of chaperone-mediated autophagy in AHR protein 
degradation in HeLa cells.  However, activation of chaperone-mediated autophagy 
by 6-AN did not alter the AHR content in HeLa cells.  In addition, starvation of HeLa 
cells for four hours caused an increase of the AHR content whereas prolonged 
starvation in rodents is known to cause chaperone-mediated autophagy (Cuervo, 
Knecht, Terlecky, & Dice, 1995).  Collectively, chaperone-mediated autophagy is 
unlikely to be involved in the degradation of AHR in HeLa cells.  Reduction of the 
LAMP2 levels in HeLa cells upon 6-AN treatment is surprising since activation of 
chaperone-mediated autophagy often increases the LAMP2A levels at the lysosomal 
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membrane (Kiffin, Christian, Knecht, & Cuervo, 2004).  Realizing that the LAMP2 
antibody we used to detect LAMP2A cannot differentiate LAMP2A from LAMP2B, we 
cannot rule out the possibility that LAMP2B may be suppressed by 6-AN treatment in 
HeLa cells. 
This p62/LC3B-mediated AHR degradation is analogous to the cargo-induced 
model of selective autophagy, which involves the formation of the K63-ubiquitinated 
client proteins that are recognized by the cargo receptors (Rogov et al., 2014).  
Although both cargo-induced and starvation-induced autophagy involve the 
formation of autophagosome and fusion of the autophagosome with the lysosome, 
the signaling cascade and the involvement of autophagy-related (Atg) proteins are 
not exactly identical (Zaffagnini & Martens, 2016).  It is evidence that AHR can be 
degraded when autophagy is induced by nutrient deprivation or treatment with 
metformin.  However, autophagy induction via nutrient deprivation quickly increases 
the amount of AHR.  During that time, HSP90 protects the AHR protein from 
degradation, consistently with the literature that inhibition of HSP90 leads to client 
protein degradation through autophagy (Jinwal et al., 2012; Qing, Yan, Qu, Liu, & 
Xiao, 2007; Qing, Yan, & Xiao, 2006) and inhibition of HSP90 by geldanamycin 
results in the proteasomal degradation of AHR (H. S. Chen, Singh, & Perdew, 1997).  
Down-regulation of HSP90 in HeLa cells exhibits more AHR degradation upon early 
nutrient deprivation; subsequently, AHR levels are steadily increased due to the up-
regulation of the AHR gene transcription.  We previously discovered that the 
protective role of p23 on the AHR levels does not require HSP90, since stable 
knockdown of HSP90 to 55% of its wild type content in HeLa cells does not alter the 
AHR levels and p23 mutants with modest HSP90 binding affinity can still effectively 
restore the AHR levels (Pappas et al., 2018).  Although we observed that 
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degradation of AHR occurs after 15-min treatment with HBSS in HSP90 knockdown 
HeLa cells, this reduction is unique to nutrient deprivation and is temporary, probably 
involving the general HSP90 protection of protein folding under stress; it is rather 
different from the previous observation that the long-term, steady-state AHR levels 
are not affected by the reduction of HSP90.  Studying the underlying mechanisms of 
how HeLa cells trigger the synthesis of AHR in response to autophagy induction by 
nutrient deprivation might reveal a potential role of AHR in the autophagy-related 
diseases, such as neurodegenerative diseases and tumorigenesis. 
Conclusions 
In summary, we uncovered a mechanism for AHR protein degradation in 
HeLa cells.  We observed that AHR is K63-ubiquitinated and binding of AHR to p62 
and LC3B-II occurs.  Inhibition of autophagy increases AHR protein levels.  These 
observations are more pronounced when p23 is down-regulated in HeLa cells, 
suggesting that reduction of the p23 content stimulates autophagy to degrade AHR.  
Other than HeLa cells, four other human cell lines also show the autophagy-
dependent regulation of the AHR protein levels and exhibit AHR–LC3B-II and AHR–
p62 interactions.  Collectively, the AHR content is controlled by selective autophagy 
– a novel understanding of how human cells maintain the AHR protein levels.  This 
mechanism can potentially be manipulated in an effort to control the AHR levels for 
clinical applications. 
Materials and Methods 
Reagents 
3MA, bafilomycin A1, and metformin were purchased from Cayman Chemical 
(Ann Arbor, MI, USA).  Chloroquine, rabbit IgG, Duolink proximity ligation assay kit, 
and anti-LC3B rabbit IgG were purchased from Sigma (St. Louis, MO, USA).  
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Cycloheximide, anti-AHR monoclonal mouse IgG (A-3x, used for proximity ligation 
assay and co-immunoprecipitation for p62 due to less interference in the region of 
p62 on Western analysis), anti-LAMP2 (H4B4), and anti-HSP90 goat IgG (N-17) 
were purchased from Santa Cruz Biotechnology (Dallas, TX, USA).  HBSS was 
purchased from Gibco (Grand Island, NY, USA).  Puromycin was purchased from 
Goldbio (St Louis, MO, USA).  FBS was purchased from Gemini Bio (West 
Sacramento, CA, USA).  HyClone DMEM, protein G Dynabeads, anti-p23 mouse 
IgG (JJ3), and all cell culture reagents (if not specified) were purchased from Thermo 
Fisher Scientific (Rockford, IL, USA).  Direct-zol RNA kit was purchased from Zymo 
Research (Irvine, CA, USA).  MMLV high-performance reverse transcriptase was 
purchased from Epicentre (Madison, WI, USA).  qPCR SYBR Green supermix was 
purchased from Bio-Rad (Hercules, CA, USA).  Zymopure maxiprep kit was 
purchased from Zymo Research (Irvine, CA, USA).  RT2 Profiler PCR array plates 
were purchased from Qiagen (Germantown, MD, USA).  K48- and K63-TUBE were 
purchased from LifeSensors (Malvern, PA, USA).  p23 shRNA, HSP90 shRNA, and 
LC3B shRNA were purchased from Dharmacon (Lafayette, CO, USA).  Anti-AHR 
rabbit IgG (SA210) and anti-p62 rabbit IgG were purchased from Enzo Life Sciences 
(Farmingdale, NY, USA).  Anti-β-actin mouse IgG was purchased from Ambion 
(Austin, TX, USA).  All secondary IgG and streptavidin conjugated with IRDye 
800CW or 680 were purchased from LI-COR Bioscience (Lincoln, NE, USA).  The 
pCMV-VSV-G (8454) and pCMV-dR8.2 dvpr packaging plasmid (8455) were 
purchased from Addgene (Watertown, MA, USA). 
Cell Culture 
All cell lines were authenticated by ATCC and were maintained at 37 C and 
5% CO2.  HeLa, A549, and T-47D cells were cultured in DMEM supplemented with 
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10% fetal bovine serum, 2 mM GlutaMAX-I, 10 U/mL of penicillin, and 10 mg/mL of 
streptomycin.  Hep3B and MDA-MB-468 cells were grown in Advanced MEM with 
5% fetal bovine serum, 2 mM GlutaMAX-I, 10 U/mL of penicillin, and 10 mg/mL of 
streptomycin.  For nutrient deprivation study, cells were rinsed with HBSS twice and 
then grown in HBSS for the designated period. 
Generation of HSP90, p23, and LC3B Stable Knockdown Cells 
Protocols for the generation of the shRNA-containing lentiviruses and lentiviral 
infection were previously described (P. M. Nguyen et al., 2012a).  p23 knockdown 
HeLa cells were generated using p23-specific shRNA (#1475); HSP90 knockdown 
HeLa cells were generated using the HSP90α-specific shRNA (#6, 8563), and LC3B 
knockdown HeLa cells were generated using the MAP1LC3B-specific shRNA 
#153286 and #151769.  In essence, AD-293 cells (about 7 × 105 cells) were plated 
in 5 mL of medium without antibiotics in a 25 cm2 flask.  After incubation at 37 C 
and 5% CO2 overnight, cells reached 50%–80% confluence.  Fresh medium without 
antibiotics was exchanged.  Cells were transfected using EndoFectin reagent (2:1 
DNA ratio) with the plasmids cocktail as follows: 2.5 μg of specific shRNA plasmid, 
1.875 μg of the pCMV-dR8.2 dvpr packaging plasmid, and 0.625 μg of the VSV-G 
envelope plasmid.  Fresh complete medium was exchanged 15 h later.  Medium 
which contained the virus was collected after 24 h and stored at 4 C.  Another 5 mL 
of fresh complete medium was added to cells and was collected 24 h afterwards.  
The combined medium was centrifuged at 400 g for 5 min to remove any AD-293 
cells that were inadvertently collected.  The resulting supernatant was used for 
infection.  The infection of HeLa cells was performed by first seeding cells in a 75 
cm2 flask to 50%–70% confluence.  Fresh complete medium containing 8 μg/mL of 
polybrene was exchanged.  Supernatant containing lentiviral particles (0.5–1 mL) 
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was then added.  The fresh complete medium was exchanged 24 h after infection.  
The selection was started by adding 1.5 μg/mL of puromycin 48–54 h after infection.  
Western analysis was performed to determine the target protein levels after 2–3 
passages. 
Transient Transfection 
Cells were grown in 6-well plates and transfection was initiated when cells 
were about 90% confluence.  Cells were transfected with 2.5 μg of DNA and 5 μL of 
EndoFectin reagent.  Fresh complete medium was exchanged 24 h after 
transfection.  Treatment with CQ was started at 48 h post-transfection and cells were 
harvested at 54 h post-transfection. 
Whole-Cell Lysate Preparation and Western Analysis 
Cell pellets were resuspended using lysis buffer (25 mM HEPES, pH 7.4, 0.4 
M KCl, 1 mM EDTA, 1 mM DTT, 10% glycerol, 1% NP-40, 1 mM PMSF, and 2 
μg/mL of leupeptin) of 2.5× volume of cell pellets.  After three cycles of freeze/thaw, 
lysates were kept on ice for 30 min and were then centrifuged at 16,000 g for 10 min 
at 4 C.  The supernatants were defined as whole-cell lysates and were subjected to 
BCA assay and LI-COR Western analysis.  The protocol for Western analysis was 
described previously (Xie, Huang, Park, Pham, & Chan, 2014) with minor 
modification.  Fifteen percent acrylamide gels were transferred for 3 h at 4 C.  After 
the wet transfer, total protein staining was performed using LI-COR Total Protein 
Stain.  Membranes for the examination of LC3B levels for autophagic flux were dried 
overnight and wet with PBS before blocking.  The transferred nitrocellulose 
membranes were blocked in PBS with 5% BSA for 1 h.  Dilutions for antibodies were 
as follows: 1:1,000 for p23 (JJ3), p62, LC3B and AHR (A-3x); 1:2,000 for AHR 
(SA210); 1:5,000 for β-actin; 1:200 for HSP90 (N-17).  If not specified, Western 
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bands were normalized using total protein stain.  Results were obtained and 
analyzed using an LI-COR Odyssey CLx imaging system. 
RT-qPCR 
RT-qPCR was performed as described previously (Pappas et al., 2018).  In 
brief, RNA was extracted using the Direct-zol kit.  Reverse transcription was 
performed from 0.5 to 1 μg of RNA using Epicentre MMLV reverse transcriptase.  
Quantitative PCR was performed with: 1 μL of cDNA from reverse transcription 
solution, 10 μL of Bio-Rad iTaq SYBR green supermix, and 0.8 pmol sequence-
specific primers (AHR primers are OL615, 5’-ACATCACCTACGCCAGTCGC-3’ and 
OL616, 5’-TCTATGCCGCTTGGAAGGAT-3’ whereas β-actin primers are OL101, 5’-
CCACACTGTGCCCATCTAGG-3’ and OL102, 5’-
AGGATCTTCATGAGGTAGTCAGTCAG-3’) using a Bio-Rad CFX Connect real-time 
PCR machine with the following protocol: 40 cycles of 90 C for 10 s/60 C for 1 min 
with fluorescence readings taken at 60 C.  The 2 −∆∆Cq method (Livak & Schmittgen, 
2001) was used to present the normalized values.  For RT2 Profiler PCR Array, 
reverse transcription was performed with 0.5 μg of RNA using Epicentre MMLV 
reverse transcriptase.  PCR master mix (1,350 μL of Bio-Rad iTaq SYBR green 
supermix, 102 μL of cDNA synthesis solution, and 1,248 μL of RNase-free water) 
was prepared and an aliquot of 25 μL was added to each well of the RT2 Profiler 
PCR Array plate.  A Bio-Rad CFX Connect real-time PCR machine was used with 
the following protocol: 95 C for 10 min, followed by 40 cycles of 95 C for 15 sec/60 
C for 1 min (ramp rate between 95 C to 60 C step was set as 1 C/sec).  Data 
analysis was performed at Qiagen GeneGlobe Data Analysis Center 
(www.qiagen.com/shop/genes-and-pathways/data-analysis-center-overview-page).  
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Immunoprecipitation and Co-Immunoprecipitation Experiments 
Immunoprecipitation was performed as described previously (Pappas et al., 
2018). In brief, cells were lysed with the method described above.  Three 
deubiquitylase inhibitors, namely 1,10-phenanthroline (5 mM), NEM (10 mM), and 
PR-619 (50 μM) were added in the lysis buffer for immunoprecipitation experiment 
with K48- and K63-TUBE Far-western analysis.  One to two milligrams of whole-cell 
lysates were used for immunoprecipitation (IP) and co-immunoprecipitation (co-IP) of 
AHR using anti-AHR antibody SA210 (1:200 by volume) or anti-AHR antibody A-3x 
(1:100 by volume for AHR–p62 co-IP) for 30 min at room temperature.  The pre-
equilibrated Protein G Dynabeads (1:200 by volume) were then added to each 
sample with the assay buffer: 25 mM HEPES, pH 7.4, 0.15 M NaCl, 1 mM EDTA, 1 
mM DTT, 10% glycerol, 0.1% Tween-20 for IP (0.05% Tween-20 for co-IP), and 1 
mg/mL of BSA.  The samples were incubated with a rotation of 60 rpm overnight at 4 
C.  The beads were then washed three times for 5 min each with the assay buffer 
and then eluted with electrophoresis sample buffer for SDS-PAGE, followed by LI-
COR Western analysis. 
K48- and K63-TUBE and Far-Western Analysis 
HeLa cells were seeded and cultured overnight in a 75 cm2 flask.  Treat the 
cells with DMSO (0.1%), 3MC (1 μM), and/or MG132 (10 μM) for 2 h and then 
harvested with cold PBS.  Cell lysates were obtained using a lysis buffer (see above) 
with a 4× volume of the cell pellet.  Immunoprecipitation was performed as described 
above, followed by Far-western analysis.  K48- or K63-TUBE (1:1,000) were 
incubated with the nitrocellulose membrane for 1 h at room temperature and then 
with IRDye-800 conjugated streptavidin (1:10,000) for 2 h at room temperature.  The 
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wash step between incubation was the same as in Western analysis.  Results were 
obtained and analyzed using an LI-COR Odyssey CLx imaging system. 
Proximity Ligation Assay 
Cells were seeded on round microscope glass coverslips placed in wells of a 
12-well plate and grown to about 80% confluence.  Cells were then rinsed with PBS 
twice and incubated with ice-cold 100% methanol for 5 min.  After one rinse with 
PBS, cells were ready for proximity ligation assay using Duolink in situ kit.  In brief, 
cells were incubated with Duolink blocking solution (40 μL) at 37 C for 60 min, 
followed by incubation with the two antibodies (in Duolink antibody diluent) used for 
interaction study (40 μL) at 37 C for 60 min using the following dilution: mouse anti-
AHR A-3x (1:100), rabbit anti-p62 (1:100), and rabbit anti-LC3B (1:100).  After that, 
we performed steps involving Duolink probe incubation, ligation, and amplification 
according to the manufacturer’s recommendation.  Nucleus staining was performed 
by adding 1 μg/mL of DAPI in water to cells for a 1 min incubation.  Coverslips were 
mounted using 6 μL of PBS and were sealed with nail polish.  Samples were viewed 
using a KEYENCE BZ-X700 fluorescence microscope and results were analyzed by 
ImageJ software. 
Statistical Analysis 
GraphPad Prism 8 software (La Jolla, CA) was utilized for statistical analysis.  
Two-tailed unpaired t-test, multiple t-tests corrected with the Holm-Sidak method for 
multiple comparisons, and one-way and two-way (or mixed-model) ANOVA with 
Sidak, Tukey or Dunnett tests for multiple comparisons were used to determine 
statistical significance with *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, and ns, 
not significant (p > 0.05). 
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CHAPTER 3: GLYCOGEN SYNTHASE KINASE 3 BETA REGULATES THE 




The aryl hydrocarbon receptor (AHR) is a cytosolic receptor which is involved 
in diverse cellular events in humans.  The most well-characterized function of AHR is 
its ability to upregulate gene transcription after exposure to its ligands, such as 
environmental toxicants, dietary antioxidants, drugs, and endogenous ligands.  The 
cellular content of AHR is partly controlled by its degradation via the ubiquitin–
proteasome system and the lysosome-dependent autophagy.  We used human 
cervical cancer (HeLa) cells to investigate how AHR undergoes protein degradation 
and how its activity is modulated.  Since the glycogen synthase kinase 3 beta 
(GSK3β)-mediated phosphorylation can trigger protein degradation and substrates of 
GSK3β contain stretches of serine/threonine residues which can be found in AHR, 
we examined whether degradation and activity of AHR can be controlled by GSK3β.  
We observed that AHR undergoes the GSK3β-dependent, LC3-mediated lysosomal 
degradation without ligand treatment.  The AHR can be phosphorylated in a GSK3β- 
dependent manner at three putative sites (S436/S440/S444, S689/S693/T697, and 
S723/S727/T731), which leads to lysosomal degradation of the AHR protein.  
Inhibition of the GSK3β activity suppresses the ligand-activated transcription of an 
AHR target gene in HeLa, human liver cancer (Hep3B), and human breast cancer 
(MCF-7) cells.  Collectively, our findings support that phosphorylation of AHR by 
GSK3β is essential for the optimal activation of its target gene transcription and this 
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phosphorylation may partake as an “off” switch by subjecting the receptor to 
lysosomal degradation. 
Introduction 
The aryl hydrocarbon receptor (AHR) is a cellular sensor of environmental 
pollutants/carcinogens, endogenous ligands, and numerous dietary flavonoids and 
their derivatives (Murray & Perdew, 2020).  Upon ligand binding, the AHR cytosolic 
complex changes conformation to reveal its nuclear localization motif, resulting in 
nuclear entry.  The nuclear AHR dimerizes with aryl hydrocarbon receptor nuclear 
translocator (ARNT) to form an active transcription factor: it binds to the dioxin 
response element, recruits co-activators locally to alter chromatin structure, and 
eventually allows optimal assembly of the preinitiation complex for gene 
transcription.  Although AHR is best known for its action as a ligand-activated 
transcription factor which regulates transcription of xenobiotic metabolizing enzyme 
genes, the biological role of this receptor is rather complex, and yet very interesting.  
For example, recent reports show that AHR plays an intricate role in seemingly 
diverse biological processes and diseases, namely autoimmune diseases (Iyer et al., 
2018; Kahalehili et al., 2020; Rosser et al., 2020), cancers and cell proliferation 
(Garcia-Villatoro et al., 2020; Huerta-Yepez et al., 2020; Nothdurft et al., 2020; Sári 
et al., 2020; X. Zhang et al., 2021), cancer stem cell differentiation (Ly et al., 2019), 
respiratory disorders (Castañeda et al., 2018; Iu et al., 2017), atopic dermatitis 
(Smith et al., 2017; Takei et al., 2015; van den Bogaard et al., 2013), bone disorders 
(Y. Jia et al., 2019), antiviral response (Giovannoni et al., 2020), and adipocyte 
differentiation (Dou et al., 2019).  This receptor is even implicated in the SARS-CoV-
2 pathophysiology (Anderson, Carbone, & Mazzoccoli, 2021).  Obviously AHR has 
become an attractive target for drug development; thus, any means to modulate its 
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function in selective tissues is highly desirable.  AHR normally translocates into the 
nucleus after ligand binding, followed by degradation via the ubiquitin-proteasome 
system (Davarinos & Pollenz, 1999; Q. Ma & Baldwin, 2000; Roberts & Whitelaw, 
1999a).  Interestingly, even without addition of an exogenous ligand, we showed that 
AHR undergoes lysosomal degradation in various untransformed and immortalized 
cell lines (J. Chen, Yang, Russu, & Chan, 2021; Yang & Chan, 2020).  An in-depth 
understanding of the regulation of the cellular AHR content should unveil ways to 
modulate the AHR function by controlling its protein levels. 
Glycogen synthase kinase 3 beta (GSK3β) is a serine/threonine kinase which 
was first discovered to regulate gluconeogenesis by phosphorylation of glycogen 
synthase (EMBI, RYLATT, & COHEN, 1980).  Since then, more than five hundred 
GSK3β substrates have been suggested based on the motif-based predictions 
(Linding et al., 2007), which make this kinase one of the most complicated kinases 
for cellular processes.  One of its most notable substrates is β-catenin.  Upon 
phosphorylation by GSK3β, β-catenin is degraded via the ubiquitin-proteasome 
system; GSK3β is therefore recognized as a key player in the regulation of β-catenin 
function, particularly in the promotion of cancer growth (Takahashi-Yanaga, 2013).  
Our laboratory is interested in studying the underpinnings of AHR degradation in 
controlling its basal levels within a cell.  Realizing that GSK3β is responsible for β-
catenin degradation, we hypothesized that events such as GSK3β phosphorylation 
may play a role in AHR degradation since the carboxyl region of AHR is serine and 
threonine rich.  Here, we provide evidence supporting that GSK3β is responsible for 
AHR phosphorylation, which directs AHR to lysosomal degradation.  This 
phosphorylation is essential for the optimal transcription of AHR target gene upon 
ligand activation. 
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Figure 3.1.  GSK3β phosphorylation sites 
Results 
GSK3β Regulates the AHR Protein Levels in HeLa Cells 
When we examined the GSK3β phosphorylation sites of β-catenin and the 
general requirement of a GSK3β substrate (Beurel, Grieco, & Jope, 2015a), we 
identified three similar stretches of serine/threonine regions of the human AHR which 
would hint AHR as a potential substrate of GSK3β (Figure 3.1).  With the 
understanding that the phosphorylated β-catenin by GSK3β undergoes protein 
degradation, we first examined whether the AHR protein levels can be reduced by 
GSK3β.  After treating HeLa cells with 10–40 μM tideglusib (TDG), which is a 
specific GSK3β inhibitor (Beurel et al., 2015a), AHR protein levels were significantly 
increased to 1.7-fold (Figure 3.2A).  Another GSK3β inhibitor lithium chloride (LiCl) 
also significantly increased the AHR protein levels to 1.5-fold (Figure 3.2B).  
Downregulation of GSK3β by a sequence-specific shRNA significantly increased the 
AHR protein levels to two-fold when compared to the scramble shRNA negative 
control (Figure 3.2C).  The AHR protein levels were significantly suppressed to 60% 
of the wild-type content when the HA-tagged GSK3β was transiently expressed 
(Figure 3.2D).  Collectively, these results strongly supported that GSK3β 
downregulates the AHR protein content in HeLa cells. 
 
                                                   .  (A) GSK3β phosphorylation consensus 
sequence.  (B) GSK3β phosphorylation sites of β-catenin.  (C) Three putative 
GSK3β phosphorylation sites of the human AHR (amino acid 1–848) which show  
A. N terminus-...-S/T-X-X-X-S/T(P)-...-C terminus
C. AHR
B. β-catenin LDSGIHSGATTTAPSLS








Figure 3.2.  AHR protein levels are regulated by GSK3β in HeLa cells 
(Figure 3.1 Continued) 
 
best match to the consensus sequence.  The numbers indicate the amino acid 
locations of the primary sequence.  Orange font represents the serine and threonine 
sites for GSK3β phosphorylation.  S45 (bold) of β-catenin represents the priming site 
of casein kinase 1.  Phosphorylation of the priming site is necessary for GSK 
phosphorylation. 
 
                                                                                                     .  (A) HeLa 

























































































(Figure 3.2 Continued) 
 
showed that AHR protein levels increased after TDG treatment.  The images are 
representative of the replicate data (means ± SD, n = 3).  DMSO group (treated for  
8h) was arbitrarily set as one (with no error bar) for data normalization.  One-way 
ANOVA with Dunnett multiple comparisons test was per-formed to determine 
statistical significance.  (B) AHR protein levels increased after 6-h, 5 mM LiCl 
treatment.  The images are representative of the replicate data (means ± SD, n = 3).  
No LiCl (no treatment) group was arbitrarily set as one (with no error bar) for data 
normalization.  Un-paired t-test with Welch’s correction was used to determine the 
statistical significance.  (C) Transient knockdown of GSK3β (after 72 h) increased 
AHR protein levels.  The images are representative of the replicate data (means ± 
SD, n = 3).  Cells transfected with scramble shRNA were used as the negative 
control and was arbitrarily set as one (with no error bar) for data normalization.  
Unpaired t-test with Welch’s correction was used to determine the statistical 
significance.  (D) Transient expression of HA-GSK3β (after 72 h) decreased AHR 
protein levels.  The images are representative of the replicate data (means ± SD, n = 
3) in one experiment and was repeated two more times with similar results. No 
plasmid group (NP) represents cells undergoing the same transient transfection 
without a plasmid.  Unpaired t-test was used to determine the statistical significance.  
For A to D, each Western lane contained 30 μg of whole-cell lysate.  Data in A for 
10–20 μM treatment groups were normalized by β-actin (as shown) whereas the rest 
of the data were normalized by total protein stain. 
 
GSK3β Causes the Autophagy-Mediated Lysosomal Degradation of AHR in 
HeLa Cells 
Next, we examined whether GSK3β would suppress the AHR levels by 
promoting AHR degradation.  We performed experiments using a proteasome 
inhibitor MG132 and an autophagy inhibitor chloroquine (CQ).  We observed that 
MG132 surprisingly decreased the amount of AHR protein in HeLa cells that were 
transiently transfected with either a plasmid carrying the HA fusion of GSK3β cDNA 
or with no plasmid (Figure 3.3A).  CQ, however, increased the AHR protein levels in 
HeLa cells with or without HA-GSK3β expression (Figure 3.3A), suggesting that AHR 
undergoes the GSK3β-dependent lysosomal degradation, but not proteasomal 
degradation, in HeLa cells without addition of an AHR ligand.  Treatment with CQ 
increased the AHR protein levels in the HeLa cells which had undergone transfection 
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Figure 3.3.  AHR undergoes the LC-3-mediated autophagy after GSK3β 
phosphorylation 
but with no plasmid, suggesting that AHR is actively undergoing lysosomal 
degradation.  To ensure that on our hand, MG132 could inhibit proteasomal 
degradation in Figure 3.3A, we examined the change of the β-catenin protein levels 
in HeLa cells and confirmed that MG132 reversed the GSK3β-mediated reduction of 
the β-catenin levels (Figure 3.3B).   
 
                                                                                                                                          
                         .  (A) AHR protein levels ± HA-GSK3β transient expression (72 h) 
were increased by CQ (40 μM for 6 h, last 6 h of the 72-h period of transient 
transfection) but not by MG132 (10 μM for 6 h, last 6 h of the 72-h period of transient 
transfection).  The time and dose of CQ and MG132 were optimized for inhibition of 


































































































(Figure 3.3 Continued) 
 
3) in one experiment and was repeated once with similar results.  DMSO treatment 
group (treated for 6 h) was arbitrarily set as one for data normalization.  No plasmid 
(NP) group represents cells undergoing the same transient transfection as HA-
GSK3β but without plasmid.  Two-way ANOVA with Dunnett multiple comparisons  
test was performed to determine statistical significance.  (B) β-catenin protein levels 
decreased after HA-GSK3β transient expression (72 h) and were increased ± HA-
GSK3β by MG132 (10 μM for 6 h, last 6 h of the 72-h period of transient 
transfection).  The images are representative of the replicate data (means ± SD, n = 
5).  DMSO treatment group was arbitrarily set as one for data normalization. No 
plasmid (NP) group rep-resents cells undergoing the same transient transfection as 
HA-GSK3β but without plasmid.  Two-way ANOVA with Sidak multiple comparisons 
test was performed to determine statistical significance.  (C) LC3B-II level with HA-
GSK3β transient expression (72 h) was higher than that in the no plasmid group 
(NP).  No plasmid (NP) group represents cells undergoing the same transient 
transfection as HA-GSK3β but without plasmid.  The fold change of LC3B-II increase 
after 6-h, 40 μM CQ treatment was also higher in the HA-GSK3β group.  The images 
are representative of the replicate data (means ± SD, n = 3) in one experiment and 
was repeated once with similar results.  No treatment (NT) group (treated for 6 h) 
was arbitrarily set as one for data normalization.  Two-way ANOVA with Tukey 
multiple comparisons test was performed to determine statistical significance.  (D) 
Immunoprecipitation of AHR from HeLa whole cell lysates ± GSK3β knockdown 
using anti-AHR SA210 polyclonal antibody, followed by K63-TUBE Far-western 
analysis showing less K63-ubiquitinated AHR in GSK3β knockdown group while 
more AHR (104 kDa) being precipitated when compared to the scramble shRNA-
transfected group.  The images are representative of the replicate data (means ± 
SD, n = 3) with scramble shRNA group set as one for normalization of three 
separate experiment (thus no error bar).  For (A–C), each Western lane contained 30 
μg of whole-cell lysate. Data were normalized by total protein stain. 
 
Next, we examined whether GSK3β could trigger autophagy in HeLa cells by 
measuring the LCB-II levels, which correspond to the autophagic flux.  We observed 
that the LC3B-II protein levels in HA-GSK3β expressing cells were increased (1.7-
fold) when compared to cells that had undergone transfection with no plasmid 
(Figure 3.3C, NT).  After 6 h of CQ treatment, the increase of LC3B-II was much 
higher in the HA-GSK3β group, suggesting that GSK3β causes an increase of the 
autophagic flux in HeLa cells.  Next, we examined whether the K63-ubiquitination of 
AHR would occur, which might lead to its lysosomal degradation.  We performed 
Far-western analysis using lysine (K) 63 specific tandem ubiquitin binding entity 
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(TUBE) conjugated to biotin.  This K63 TUBE reagent has a 1000–10,000-fold 
binding affinity favoring the K63-linked ubiquitin than the other linkages.  After 
immunoprecipitation using the SA-210 AHR antibody, GSK3β knockdown lysate 
showed higher amount of AHR while the K63-ubiquitinated AHR was less when 
compared to the scramble shRNA transfected group (Figure 3.3D).  The ratio of K63-
ubiquitinated AHR/total AHR decreased after GSK3β knockdown, supporting that 
GSK3β promotes the K63-ubiquitination of AHR.  Collectively, our results support 
that GSK3β causes the AHR degradation in lysosome via the K63-dependent, LC3-
mediated autophagy. 
GSK3β Phosphorylates AHR in HeLa Cells 
Next, we examined whether AHR could be phosphorylated by GSK3β.  Phos-
tag reagent, which has been successfully used by other researchers to detect 
phosphorylated proteins (Jinwal et al., 2011; Li et al., 2016), was used to detect the 
phosphorylated AHR.  In principle, phos-tag reagent binds selectively to the 
phosphate group(s) of protein and retards the bound protein during electrophoresis 
when the reagent was embedded evenly in the acrylamide gel.  First, we confirmed 
that the phosphorylated β-catenin could be detected using this approach with a 7.5% 
acrylamide gel containing 20 μM phos-tag reagent (Figure 3.4A).  Then we used the 
same strategy to detect the phosphorylated AHR.  There were three bands detected 
using the anti-AHR SA-210 antibody at the top region of the immunoblot, indicated 
by red dots (Figure 3.4B).  These higher mobility bands were not observed in a 
conventional acrylamide gel without phos-tag reagent.  Intensity of the putative 
phosphorylated AHR region showed a time- and dose-dependent decrease after 
phosphatase (λ-PP) treatment, supporting that these bands represent the 
phosphorylated AHR (Figure 3.4B).  After λ-PP treatment, the top region intensities 
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were weaker while the unphosphorylated AHR band intensity increased.  Thus, we 
quantified our data by the ratio of the intensity of the phosphorylated region to the 
intensity of the total AHR, which was the combined intensity of phosphorylated and 
unphosphorylated AHR.  Inhibition of GSK3β by TDG yielded more 
unphosphorylated AHR and showed that the phosphorylated AHR/total AHR value 
decreased to about 50% (Figure 3.4C).  Transient expression of the HA fusion of 
GSK3β increased the phosphorylated AHR region intensity and decreased the 
unphosphorylated AHR intensity.  The phosphorylated AHR/total AHR value 
increased to 2-fold when HA-GSK3β was transiently expressed (Figure 3.4D).  






Figure 3.4.  Phosphorylation of AHR is affected by GSK3β activity 
(Figure 3.4 Continued) 
 
                                                                                                .  7.5% acrylamide 
bis-Tris gel embedded with 20 μM phos-tag reagent was used to confirm the 
phosphorylation of AHR.  (A) Phosphorylated (p-β-catenin) and unphosphorylated β-
catenin can be separated, and the intensities of three phosphorylated bands (red 
dots) were significantly decreased by 1 μL (80 units) of λ-PP treatment for 2, 30 or 
60 min at 30 °C.  NT represents no treatment.  The top region of AHR blot in B-D 
shows three prominent phosphorylated AHR bands (p-AHR, red dots).  The whole 
top region indicated by the red bracket is defined as the phosphorylated region and 
unphosphorylated AHR is indicated with the black dot.  The y-axis (p-AHR/total AHR) 
represents intensity of the phosphorylated bracket region divided by the sum of the 
intensities of the bracket region plus unphosphorylated AHR.  (B) Time- and dose-
dependent decrease of the p-AHR/total AHR value after 1 μL (80 units) or 5 μL (400 
units) of λ-PP treatment for 2, 30 or 60 min for 30 °C.  The images are representative 
of the replicate data (means ± SD, n = 3).  Two-minute of no λ-PP treatment group 
was arbitrarily set as one (with no error bar) for data normalization.  Two-way 
ANOVA with Dunnett multiple comparisons test was performed to determine 
statistical significance.  (C) After 40 μM TDG treatment for 8 h, the p-AHR/total AHR 
values decreased.  The images are representative of the replicate data (means ± 
SD, n = 4).  DMSO group (treated for 8 h) was arbitrarily set as one (with no error 
bar) for data normalization.  Unpaired t-test with Welch’s correction was used to 
determine the statistical significance.  (D) Transient expression of HA-GSK3β 
increased the p-AHR/total AHR value.  The images are representative of the 
replicate data (means ± SD, n = 5).  No plasmid group (NP), which represents cells 
undergone same transient transfection protocol without the plasmid carrying HA-
GSK3β cDNA, was arbitrarily set as one for data normalization.  Unpaired t-test with 
Welch’s correction was used to determine the statistical significance.  For (A–D), 
each Western lane contained 40 μg of whole-cell lysate.  Data were normalized by 




















































Mutational Analysis Reveals Three Putative GSK3β Phosphorylation Regions 
of AHR 
To further investigate whether AHR would be a substrate of GSK3β, we used 
two truncated human AHR, namely CΔ553 (amino acid 1–295) and NΔ515 (amino 
acid 516–848), that were fused to GFP to approximate the phosphorylation 
location(s) (Figure 3.5A).  Neither of these two GFP fusions responded to TDG 
inhibition (Figure 3.5B,C) whereas both the endogenous AHR and GFP-AHR 
controls did (Figure 3.5B–D).  There are three stretches of serine and threonine 
residues of AHR that fulfill the requirement of an GSK3β substrate: they are 
S436/S440/S444, S689/S693/T697, and S723/S727/T731 (Figure 3.1).  These 
locations match the consensus GSK3β recognition motif and the GSK3β 
phosphorylation sites of β-catenin.  We mutated these serine and threonine residues 
to alanine and generated three GFP fusion mutants, namely M1 
(S436A/S440A/S444A), M2 (S689A/S693A/T697A), and M3 (S723A/S727A/T731A) 
(Figure 3.5A).  After treatment with 40 μM TDG, only HeLa cells transfected with the 
M2-GFP fusion showed no statistically significant increase whereas M1- and M3-
GFP fusions showed modest increase after GSK3β inhibition by TDG (1.26- to 1.34-
fold), when compared to the endogenous AHR and AHR-GFP fusion with a 








Figure 3.5.  Site-directed mutagenesis reveals three putative GSK3β 
phosphorylation sites of AHR 
                                                                                                                                           
                                            .  (A) A map showing GFP fusion expressing plasmids 
of full length human AHR and two truncated derivatives (pGFP2-N2-AHR, pGFP2-
C2-CΔ553, and pGFP2-N2-NΔ515) and three AHR mutant GFP plasmids (S436A-
S440A-S444A, M1; S689A-S693A-T697A, M2; S723A-S727A-T731A, M3).  The 
names of the plasmid expressing the corresponding protein are listed on the left.  
Both GFP fusions of CΔ553 (B) and NΔ515 (C), 56 h after transient transfection, did 
not respond to TDG while the full-length AHR-GFP after transiently transfecting 
pGFP2-N2-AHR plasmid for 56 h (D) showed simi-lar increase as the endogenous  
pGFP2-N2-wt-AHR 1 848 GFP
pGFP2-N2-ND515 516 848 GFP
pGFP2-N2-M1 1 848X XX
S436A/S440A/S444A
GFP









(Figure 3.5 Continued) 
 
AHR proteins after TDG (40 μM, 8 h) treatment.  The images are representative of 
the replicate data (means ± SD, n = 3) in one experiment, which was repeated once 
with similar results.  DMSO treatment group was arbitrarily set as one for data 
normalization.  NT represents no transfection.  One-way ANOVA with Sidak multiple 
comparisons test was performed to determine statistical significance.  (E) M1-GFP 
mutant showed lowered in-crease (by 20%) when compared to endogenous AHR but 
similar increase as AHR-GFP (data from 3.5D) after TDG (40 μM, 8 h) treatment.  
(F) For M2-GFP mutant, the TDG (40 μM, 8 h) increase was minimal.  The increase 
level was significantly lower comparing to AHR-GFP (data from 3.5D).  (G) M3-GFP 
mutant showed 27% less increase comparing to the endogenous AHR and 13% less 
increase as AHR-GFP (data from 3.5D) after TDG (40 μM, 8 h) treatment.  The 
images in (E–G) are representative of the replicate data (means ± SD, n = 6).  
DMSO treatment groups were arbitrarily set as one for data normalization.  Two 
experiments of n = 3 each were performed so that error bars are present on the 
DMSO groups.  The dotted lines separate the AHR-GFP transfection data that are 
presented in 3.5D for easy reference.  One-way ANOVA with Sidak multiple 
comparisons test was performed to determine statistical significance.  For B to G, 
each Western lane contained 30 μg of whole-cell lysate.  Data were normalized by 
total protein stain.  NΔ515-GFP (5C) was detected by the GFP antibody since this 
construct cannot be detected by SA210 AHR antibody while all other GFP fusions of 
AHR and derivatives were detected by SA210 AHR antibody. 
 
Next, we examined whether resistance to GSK3β control would translate into 
resistance to lysosomal degradation.  Our results showed that levels of GFP fusions 
of CΔ553 and NΔ515 after transient transfection into HeLa cells were not altered 
after CQ, which is an autophagy inhibitor, treatment whereas the endogenous AHR 
and AHR-GFP fusion showed higher levels after CQ treatment (Figure 3.6A–C).  In 
addition, unlike the endogenous AHR in HeLa cells which showed about 2–2.5-fold 
increase upon CQ treatment, levels of the GFP fusions of all three mutants (M1-M3) 
after transient transfection were only modestly increased (1.23- to 1.27-fold) (Figure 
3.6D–F) while the AHR-GFP levels were increased by 1.8-fold in the presence of 
CQ.  Collectively, these results revealed three putative GSK3β phosphorylation 
regions of AHR which are essential for the lysosomal degradation of AHR. 
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Figure 3.6. GFP fusions of two truncated AHR and three mutants were less sensitive 
to lysosomal degradation 
 
                                                                                                                                      
                                      .  HeLa cells that were transiently transfected (for 54 h) with 
the plasmid expressing GFP-CΔ553 (A), NΔ515-GFP (B) or full length AHR-GFP (C) 
were treated with either no treatment (NT) or 40 μM CQ for 6 h.  Only AHR-GFP 
showed similar increase as the endogenous AHR upon TDG treatment.  The images 
are representative of the replicate data (means ± SD, n = 3) in one experiment, and 
was repeated once with similar results.  No treatment group (NT) was arbitrarily set 
as one for data normalization.  One-way ANOVA with Sidak multiple comparisons 
test was performed to determine statistical significance.  HeLa cells that were 
transiently transfected (for 54 h) with the plasmid expressing M1-GFP (D), M2-GFP 
(E) or M3-GFP (F) showed a significant lower increase of 1.2- to 1.3-fold when 
compared to 2.0- to 2.5-fold in-crease of endogenous AHR upon treatment with 40 
μM CQ for 6 h.  These increases were significantly less when compared to AHR-
GFP (data from 3.6C).  The images in (D–F) are representative of the replicate data 
(means ± SD, n = 6).  No treatment groups (NT) were arbitrarily set as one for data 
normalization.  Two experiments of n = 3 each were performed so that error bars are 
present on the NT groups.  The dotted lines separate the AHR-GFP transfection data 
that are presented in 3.6C for easy reference.  One-way ANOVA with Sidak multiple 
comparisons test was performed to determine statistical significance.  For (A–F),  
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(Figure 3.6 Continued) 
 
each Western lane contained 30 μg of whole-cell lysate.  Data were normalized by 
total protein stain.  NΔ515-GFP (3.6B) was detected by the GFP antibody since this 
construct could not be detected by SA210 AHR antibody while all other GFP fusions 
of AHR and derivatives were detected by SA210 AHR antibody. 
 
p23 Is Essential for the GSK3β-Mediated Degradation of AHR in HeLa Cells 
We previously reported that the basal AHR protein levels are regulated by 
selective autophagy and this degradation is more pronounced in the stable p23 
knockdown (p23KD) HeLa cells, resulting in about 50% of the AHR content when 
compared to the wild type content (Yang & Chan, 2020).  When we treated the 
p23KD HeLa cells with TDG (10–40 μM), only 40 μM TDG increased AHR protein 
level significantly to 1.3-fold (Figure 3.7A), which was lower than what we observed 
in HeLa cells (1.7-fold, Figure 2A).  LiCl (5 mM), on the other hand, could not alter 
the AHR protein levels in p23KD HeLa cells (Figure 3.7B).  Transient expression of 
the HA fusion of GSK3β in p23KD HeLa cells decreased the β-catenin protein levels 
as expected.  However, the AHR protein levels were not altered (Figure 3.7C).  
Consistently, LiCl caused an increase of the β-catenin protein levels in p23 KD HeLa 
cells (Figure 3.7D) but elicited no effect on the AHR protein levels.  To further 
confirm that p23 is essential for the GSK3β effect on AHR, we examined whether 
this GSK3β effect could be observed in p23 knockdown cells if the p23 levels were 
restored.  We transiently transfected the plasmid expressing the GFP fusion of p23 
into p23 stable knockdown HeLa cells and confirmed the expression of p23-GFP 
(Figure 3.7E).  After transient expression of p23-GFP, the AHR protein levels 
became sensitive to 20 μM TDG treatment: the AHR protein levels were increased 
to1.8-fold, which was similar to the response we observed in wild type HeLa cells 
(Figure 3.2), supporting that this AHR regulation by GSK3β is p23-dependent. 
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Figure 3.7.  Down-regulation of p23 in HeLa cells causes AHR not responsive to 
GSK3β regulation 
 
                                                                                                                                   
                            .  (A) AHR protein levels were not altered by 8-h treatment with 10 
μM or 20μM TDG in p23 stable knockdown (p23KD) HeLa cells.  Treatment with 40 
μM TDG increased AHR protein levels to 1.3-fold.  The images are representative of 
the replicate data (means ± SD, n = 3).  DMSO group (treated for 8 h) was arbitrarily 
set as one (with no error bar) for data normalization.  One-way ANOVA with Dunnett  


















































































(Figure 3.7 Continued) 
 
multiple comparisons test was performed to determine statistical significance.  (B) 
Treatment with 5 mM LiCl for 6 h did not alter AHR protein levels in p23KD HeLa 
cells.  The images are representative of the replicate data (means ± SD, n = 3).  No 
LiCl (no treatment) group was arbitrarily set as one (with no error bar) for data 
normalization.  Unpaired t-test with Welch’s correction was used to determine the 
statistical significance.  (C) β-catenin protein levels decreased while AHR protein 
levels showed no significant difference after transient expression of HA-GSK3β (72 h 
after transient transfection) in p23KD HeLa cells.  The images are representative of 
the replicate data (means ± SD, n = 3).  No plasmid group (NP) represents cells 
undergoing the same transient transfection protocol without the HA-GSK3β 
expressing plasmid and was arbitrarily set as one (with no error bar) for data 
normalization.  Unpaired t-test with Welch’s correction was used to determine the 
statistical significance.  (D) β-catenin protein levels increased in p23KD HeLa cells 
after treatment with 5 mM LiCl for 6 h.  The images are representative of the 
replicate data (means ± SD, n = 3 in one experiment, which was repeated once with 
similar results).  No LiCl (no treatment) group was arbitrarily set as one for data 
normalization.  Unpaired t-test was used to determine the statistical significance.  (E) 
p23KD HeLa cells were transiently transfected with the plasmid expressing GFP or 
GFP-p23.  Transient expression of GFP-p23 caused AHR protein levels to increase 
when cells were treated 20 μM TDG for 8 h.  The images are representative of the 
replicate data (means ± SD, n = 3 in one experiment, which was repeated once with 
similar results).  DMSO treatment group of GFP-transfected cells was arbitrarily set 
as one for data normalization.  Two-way ANOVA with Sidak multiple comparisons 
test was performed to determine statistical significance.  For (A–E), each Western 
lane contained 30 μg of whole-cell lysate.  Data in A were normalized by β-actin (as 
shown) whereas the rest of the data were normalized by total protein stain. 
 
GSK3β-Mediated AHR Phosphorylation Is Necessary for Optimal Activation of 
the AHR Target Gene Transcription in Human Cervical, Liver, and Breast 
Cancer Cells 
Next, we examined whether the AHR function could be regulated by GSK3β.  
To do this, we measured the prototypical induction of the cytochrome P450 1A1 
gene transcription by an AHR ligand in HeLa cells in the presence or absence of 
TDG.  We observed that the cytochrome P450 1A1 (cyp1a1) transcript was induced 
in HeLa cells, as expected, by two well-known AHR ligands beta-naphthoflavone 
(βNF) and 3-methylcholanthrene (3MC) to 5- and 19-fold, respectively, and this 
induction was suppressed effectively by a classical AHR antagonist CH223191 
 94 
(Figure 3.8A,B).  However, TDG alone did not alter the cyp1a1 transcript levels but 
significantly suppressed the βNF (5-fold to 3-fold) and 3MC (19-fold to 7-fold) 
dependent cyp1a1 gene transcription.  The effect of TDG and CH223191 was 
synergistic, which was particularly apparent in the case of the 3MC-induced cyp1a1 
gene transcription.  This observation suggested that TDG and CH223191 likely 
inhibit the AHR function via different mechanisms.  Downregulation of GSK3β 
expression via a GSK3β specific shRNA in HeLa cells significantly suppressed the 
ability of an AHR ligand (βNF, benzo[a]pyrene (BaP) or 3MC) to induce the cyp1a1 
gene transcription (Figure 3.8C-E).  Furthermore, knockdown of GSK3β abolished 
the TDG suppression of the 3MC-mediated AHR activity (Figure 3.8F).  In addition to 
what we observed in HeLa cells, this suppression of the 3MC activation of cyp1a1 
gene transcription by TDG was also observed in Hep3B (180-fold to 92-fold) and 
MCF-7 (1864-fold to 961-fold) cells (Figure 3.8G,H).  Collectively, our results showed 
that phosphorylation of AHR by GSK3β is essential for optimal AHR activity in terms 
of the ligand-activated gene transcription. 
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Figure 3.8.  Reduction of GSK3β activity suppresses the ligand-dependent 
activation of AHR target gene transcription 
(Figure 3.8 Continued) 
 
 
                                                                                                                                           
                                                                   .  For A and B, HeLa cells were treated 
with 40 μM TDG for 9 h.  At 5-h post-TDG treatment, cells were treated with either 
(A) 10 μM βNF, 10 μM CH223191 or both or (B) 1 μM 3MC, 10 μM CH223191 or 
both.  TDG were able to partially block the increase of the cyp1a1 message levels 
triggered by βNF and 3MC.  Co-treatment with TDG with CH223191 further  
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(Figure 3.8 Continued) 
 
decreased the cyp1a1 message levels.  For A and B, the graphs represent replicate 
data (means ± SD, n = 3; n = 4 for DMSO, TDG + 3MC and TDG + 3MC +  
CH223191 groups in 3.8B) and DMSO group was arbitrarily set as one (with no error 
bar) for data normalization.  HeLa cells were transiently transfected for 70 h with the 
plasmid carrying scramble shRNA or GSK3β specific shRNA.  Cells were then 
treated with (C) DMSO or 10 μM βNF, (D) DMSO or 5 μM BaP, (E) DMSO or 1 μM 
3MC for 4 h.  Cells were harvested at 74-h post transfection/4-h post ligand 
treatment.  The increase level of the cyp1a1 message after ligands treatment were 
significantly lower in GSK3β knockdown groups.  For C to E, graphs represent 
replicate data (means ± SD, n = 3) with DMSO group arbitrarily set as one (with no 
error bar) for data normalization.  (F) 7.5-h treatment with TDG (40 μM, treated at 
70–77.5 h post-transfection) could not suppress the 3MC (1 μM, 3.5 h, treated at 74–
77.5 h post-transfection) induced cyp1a1 messages in GSK3β shRNA transfected 
HeLa cells as observed in scramble shRNA transfected HeLa cells.  The graph 
represents the replicate data (means ± SD, n = 3) with 3MC groups minus TDG were 
arbitrarily set as one (with no error bar) for data normalization.  Hep3B (G) and MCF-
7 (H) cells were treated 40 μM TDG for 9 h.  At 5-h post-TDG treatment, cells were 
treated with 1 μM 3MC for 4 h.  The induced cyp1a1 message levels were 
suppressed by TDG in both cell lines.  The graphs in G and H represent replicate 
data (means ± SD, n = 3) with DMSO group arbitrarily set as one (with no error bar) 
for data normalization.  For (A–H), one-way ANOVA with Sidak multiple comparisons 
test was performed to determine statistical significance. 
 
Discussion 
GSK3β generally regulates its substrate stability (via phosphorylation) by 
promoting the binding of E3 ligases, such as β-transducin repeat containing proteins 
(β-TrCP), and eventually targeting its substrates for proteasomal degradation (Beurel 
et al., 2015a).  We previously discovered that without ligand treatment, AHR protein 
levels are regulated by selective autophagy while inhibition of proteasomal 
degradation by MG132 further decreases the AHR protein content (Yang & Chan, 
2020).  This MG132 effect on AHR has also been observed with the GSK3β-
mediated AHR degradation which involved the formation of the K63-linked 
ubiquitination of AHR, revealing the flexibility of degradation mechanisms that can be 
triggered by GSK3β phosphorylation.   
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GSK3β is involved in the regulation of mammalian circadian rhythm (Iitaka, 
Miyazaki, Akaike, & Ishida, 2005).  In particular, there are at least two PAS proteins, 
namely PER2 and CLOCK, that are GSK3β substrates (Iitaka et al., 2005; Spengler, 
Kuropatwinski, Schumer, & Antoch, 2009).  These proteins are in the same family as 
AHR, making it intriguing that AHR is also regulated by GSK3β.  Another notable 
GSK3β substrate is β-catenin.  There are many aspects of functional dependence 
between AHR and β-catenin.  AHR has been shown as a β-catenin target gene in 
prostate cancer cells so that increased β-catenin activity leads to increased AHR 
expression (Chesire, Dunn, Ewing, Luo, & Isaacs, 2004).  However, increased AHR 
function promotes proteasomal degradation of β-catenin since AHR is a E3 ligase 
which recognizes β-catenin as one of its substrate proteins for degradation (Kawajiri 
et al., 2009).  Functionally speaking, AHR and β-catenin operate synergistically to 
activate the cyp1a1 gene transcription (Braeuning, Köhle, Buchmann, & Schwarz, 
2011; Procházková et al., 2011).  Interestingly, both AHR and β-catenin activities are 
controlled by protein degradation mechanisms: AHR undergoes proteasomal 
degradation after ligand activation whereas β-catenin undergoes proteasomal 
degradation, limiting its transactivation of the Wnt target genes.  Since AHR contains 
several stretches of serine and threonine residues in its transactivation region which 
are similar to the GSK3β phosphorylation sites of β-catenin, we explored whether 
GSK3β would play any role in AHR degradation.  Surprisingly, but interestingly, 
GSK3β causes AHR degradation via autophagy rather than the ubiquitin-proteasome 
system.  In an effort to validate the degradation mechanism, we captured 
proteasomal degradation using MG132 by proving that the levels of β-catenin were 
restored upon MG132 treatment.  In contrast, MG132 caused reduction of the AHR 
levels when GSK3β was inhibited by TDG, clearly supporting a mechanism that is 
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different from β-catenin degradation.  This reduction is explained by the fact that 
MG132 can trigger autophagy (Bao, Gu, Ta, Wang, & Xu, 2016), resulting in further 
degradation of AHR.  One may argue that accumulation of AHR could still be 
proteasome-mediated since increased p62 levels, which is caused by an autophagy 
inhibitor such as CQ, has been shown to increase the half-life of proteasome 
substrates (Korolchuk, Mansilla, Menzies, & Rubinsztein, 2009b).  However, while 
such substrates accumulate after MG132 treatment (Korolchuk et al., 2009b), AHR 
did not, supporting that AHR undergoes lysosomal degradation via autophagy.  We 
observed a higher autophagic flux in HA-GSK3β expressing HeLa cells.  GSK3β 
phosphorylates HIV Tat-interactive protein 60 kDa (TIP60), which in turn activates 
Unc-51 like kinase-1 (ULK1), a key autophagy-related protein that plays an important 
role in autophagy initiation.  Through this GSK3β-TIP60-ULK1 pathway, autophagy 
is induced under ER-stress or growth factor deprivation (Lin et al., 2012; Nie et al., 
2016).  However, if the GSK3β-mediated degradation of AHR were merely caused 
by induction of autophagy, p23 knockdown HeLa cells would have been more 
pronounced in the suppression of the AHR levels since AHR is more prone to 
degradation via autophagy when p23 is down-regulated (Yang & Chan, 2020).  On 
the contrary, the GSK3β-mediated AHR degradation is less apparent when the p23 
levels are downregulated.  The relationship between GSK3β and p23 in affecting 
AHR degradation is reminiscent of the role of Axin, which is part of the β-catenin 
destruction complex, in facilitating the GSK3β-mediated degradation of β-catenin 
(Kim & Jho, 2010).  Perhaps p23 plays a role in conforming the structure of AHR to 
be recognizable by GSK3β.  Collectively, our results are consistent with the 
conclusion that GSK3β phosphorylates AHR in a p23-dependent manner and in turn 
causes its lysosomal degradation, which is heightened by active GSK3β. 
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The primary sequence of AHR has multiple locations containing two or more 
serine and threonine residues that are 3–4 amino acids apart—the minimal 
requirement for GSK3β recognition.  Among them, there are three AHR regions that 
match the consensus GSK3β targeting sequence the best.  We performed 
mutational analysis to convert every serine or threonine residue into alanine in all 
three (M1-M3) regions.  Results from our deletion studies using CΔ553 (amino acid 
1–295) and NΔ515 (amino acid 516–848) revealed that amino acids between 296 
and 515 are likely essential for the GSK3β-mediated degradation of AHR since both 
deletion construct levels were unaltered upon TDG treatment.  We, however, cannot 
rule out the possibility that protein folding could be distorted in these deletion 
constructs, preventing them to be recognized for lysosomal degradation.  
Nevertheless, since M1 is located within this 296–515 region, we initially predicted 
that M1, but not M2 and M3, would contain the GSK3β phosphorylation sites.  We 
also realized that more than one region could be phosphorylated by GSK3β since 
Shaggy, a Drosophila orthologue of GSK3β, phosphorylates Cubitus interruptus (Ci) 
at two distinct regions that are more than 30 amino acids apart (J. Jia et al., 2002).  
Interestingly, all three mutants (M1-M3) showed some resistance to GSK3β inhibition 
by TDG with the order of M2 > M3 ~ M1, suggesting that M2 (rather than M1) likely 
contains the GSK3β phosphorylation sites.  Moreover, all three mutants showed 
significant, but not complete, resistance to lysosomal degradation by CQ, suggesting 
that all three regions could mediate AHR lysosomal degradation.  GSK3β 
phosphorylation often works in conjunction with another kinase, since GSK3β 
substrates are usually “primed” by a kinase, followed by GSK3β phosphorylation 
(Beurel, Grieco, & Jope, 2015b).  However, the interplay among kinases targeting 
M1-M3 is much more complicated since the reported “primed” kinase site is only few 
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amino acids away from the GSK3β site, which cannot explain how M1–3 sites could 
mutually affect one another.  We cannot rule out the possibility that M1 and M3 
regions could be targeted by a kinase which might somehow direct AHR toward 
lysosomal degradation, or abrogation of phosphorylation at the M1/M3 mutated 
regions by a kinase might cause a conformational change that would interfere with 
the GSK3β phosphorylation at the M2 region.  On the contrary, phosphorylation of 
AHR by GSK3β could cause a conformational change that would allow another 
kinase to further phosphorylate AHR. 
Inhibition of extracellular signal-regulated (Erk) kinase by inhibitors, such as 
U0126 and PD98059, increases the AHR protein levels in mouse liver cancer 
Hepa1c1c7 cells (S. Chen, Operaña, Bonzo, Nguyen, & Tukey, 2005).  Expression 
of a constitutively active form of MEK1 in Hepa1c1c7 cells reduces the AHR protein 
levels by promoting the Erk kinase-dependent phosphorylation of AHR.  
Interestingly, these researchers showed that the ligand-dependent function of AHR is 
suppressed by these Erk kinase inhibitors, similar to what we observed when GSK3β 
is inhibited or downregulated.  However, it is apparent that these Erk inhibitors can 
physically interfere with the action of a more potent AHR ligand since U0126 is an 
AHR activator whereas PD98059 is an AHR antagonist (S. Chen et al., 2005).  In our 
case, suppression of the AHR transcriptional activation is likely mediated directly 
through the action of GSK3β in phosphorylating AHR, since inhibition of GSK3β (by 
TDG) and downregulation of GSK3β showed similar degrees of suppression.  The 
treatment with TDG in the GSK3β knockdown HeLa cells did not further suppress 
the AHR transactivation function.  Moreover, the putative phosphorylation sites (M1-
M3) of AHR overlap with its region required for physical recruitment of coactivators, 
making it plausible that phosphorylation positively affects the transcriptional 
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Figure 3.9.  A proposed model of GSK3β role on AHR function and degradation 
activation of AHR (S. Chen et al., 2005).  Our results reveal interesting insights on 
how AHR signals: AHR is more active when it is phosphorylated; in other words, 
phosphorylation is a means to modulate AHR function.  In addition, phosphorylation 
of AHR is also a trigger for its own lysosomal degradation, i.e., it acts as an “off” 
switch since the half-life of the phosphorylated AHR is governed by lysosomal 
degradation (Figure 3.9).  AHR phosphorylation may work in conjunction with the 
proposed “off” switches of AHR—proteasomal degradation of AHR after ligand 
activation (Davarinos & Pollenz, 1999) and upregulation of the AHR repressor (ahrr) 
gene transcription by AHR (Evans et al., 2008). 
 
                                                                                                                        .  
AHR is phosphorylated by GSK3β in a p23-dependent manner in HeLa cells.  This 
phosphorylation is required for optimal activation of the ligand-dependent AHR target 
gene transcription.  After phosphorylation, AHR is K63-ubiquitinated and is targeted  
for the LC3-mediated selective autophagy.  When the p23 content is compromised in 
HeLa cells, AHR is more prone to degradation via autophagy, bypassing the GSK3β 
phosphorylation of AHR. 
 
Conclusions 
Phosphorylation of AHR by GSK3β occurs in HeLa cells even without 

















undergoes lysosomal degradation and is more active in the ligand-activated gene 
transcription.  Inhibition of GSK3β activity by TDG suppresses the transcriptional 
activation function of AHR in at least HeLa, Hep3B, and MCF-7 cells, suggesting that 
the role of GSK3β in AHR modulation is likely a general mechanism across many 
human cell types. 
Materials and Methods 
Reagents 
TDG, CQ, CH223191, 3MC, βNF, polybrene, N-ethylmaleimide (NEM), and 
BaP were purchased from Sigma (St. Louis, MO, USA).  LiCl was purchased from 
Fisher scientific (Rockford, IL, USA).  K63-TUBE-biotin, PR-619, and 1,10-
phenanthroline were purchased from LifeSensors (Malvern, PA, USA).  MG132 was 
purchased from Cayman Chemical (Ann Arbor, MI, USA).  Puromycin was 
purchased from Gold Bio-technology (St. Louis, MO, USA).  GSK3β shRNA, p23 
shRNA, and scramble shRNA were purchased from Dharmacon (Lafayette, CO, 
USA).  HA-GSK3β expressing plasmid (1015) was a gift from Scott Friedman 
(Addgene plasmid # 49491; http://n2t.net/addgene:49491; RRID: Addgene_49491) 
(Lang et al., 2013).  pCMV-VSV-G was a gift from Bob Weinberg (Addgene plasmid 
# 8454; http://n2t.net/addgene:8454; RRID: Addgene_8454).  pCMV-dR8.2 dvpr was 
a gift from Bob Weinberg (Addgene plasmid # 8455; http://n2t.net/addgene:8455; 
RRID: Addgene_8455).  The codon humanized pGFP2-N2 plasmid was purchased 
from BioSignal Packard (Montreal, QC, Canada).  EndoFectin transfection reagent 
was purchased from GeneCopoeia (Rockville, MD, USA).  ZymoPURE II Plasmid 
Maxiprep kit and Direct-zol RNA Miniprep kit were purchased from Zymo Research 
(Irvine, CA, USA).  MMLV high-performance reverse transcriptase was purchased 
from Epicentre (Madison, WI, USA).  iTaq Universal SYBR Green Supermix was 
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purchased from Bio-Rad (Hercules, CA, USA).  QuikChange Lightning site-directed 
mutagenesis kit (210518) was purchased from Agilent (Santa Clara, CA, USA).  
Phos-tag acrylamide (AAL-107) was purchased from FUJIFILM Wako Chemicals 
(Richmond, VA, USA).  λ-PP, anti-GSK3α/β mouse IgG (0011-A), anti-β-catenin 
mouse IgG (15B8), and anti-GFP mouse IgG (B-2) were purchased from Santa Cruz 
Biotechnology (Dallas, TX, USA).  Protein G Dynabeads and anti-p23 antibody (JJ3) 
were purchased from ThermoFisher Scientific (Rockford, IL, USA).  Anti-AHR SA-
210 rabbit polyclonal antibody was purchased from Enzo Life Sciences 
(Farmingdale, NY, USA).  Anti-β-actin mouse monoclonal antibody (AM4302) was 
purchased from Ambion (Austin, TX, USA).  Anti-LC3B rabbit IgG (L7543) and IgG 
from rabbit serum were purchased from Sigma-Aldrich (St. Louis, MO, USA).  
Nitrocellulose membrane, REVERT 700 Total Protein Stain for Western blot 
normalization, IRDye 800CW, IRDye 680 anti-rabbit, anti-mouse secondary 
antibody, and IRDye 800CW streptavidin were purchased from LI-COR Bioscience 
(Lincoln, NE, USA).  GlutaMAX-I, penicillin, and streptomycin were purchased from 
Invitrogen (Carlsbad, CA, USA).  HyClone FBS and HyClone DMEM were purchased 
from Fisher scientific (Rockford, IL, USA). 
Cell Culture 
HeLa and Hep3B cell lines were authenticated by ATCC.  MCF-7 cell line was 
obtained from ATCC.  AD-293 cells were obtained from Agilent Technologies (Santa 
Clara, CA, USA).  All cell lines were maintained in DMEM supplemented with 10% 
fetal bovine serum, 2 mM GlutaMAX-I, 10 U/mL of penicillin, and 10 mg/mL of 
streptomycin at 37 C and 5% CO2. 
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Generation of p23 Stable Knockdown Cells 
We used our previously published protocol (Yang & Chan, 2020) to generate 
new p23 stable knockdown HeLa cells for this study.  In brief, on day 1, AD-293 cells 
(about 7 × 105 cells) were seeded in 5 mL of DMEM (10% FBS) without antibiotics in 
a 25 cm2 flask and incubated at 37 C and 5% CO2 overnight.  On day 2, cells 
should reach 50–80% confluence and in fresh medium without antibiotics.  
Transfection was performed in the late afternoon using EndoFectin transfection 
reagent (2:1 DNA ratio) with the plasmid cocktail as follows: 2.5 μg of p23 shRNA 
plasmid (#1475), 1.875 μg of the pCMV-dR8.2 dvpr packaging plasmid, and 0.625 
μg of the VSV-G envelope plasmid.  Fresh complete medium was exchanged 15 h 
after transfection (day 3).  After 24 h, medium which contained the virus was 
collected (day 4) and stored at 4 C.  Another 5 mL of fresh complete medium was 
added to cells and was collected 24 h afterwards (day 5).  The combined medium 
was centrifuged at 400× g for 5 min to remove any AD-293 cells that were 
inadvertently collected.  The resulting supernatant was used for infection.  Lentiviral 
infection of HeLa cells was performed by first seeding cells in a 75 cm2 flask to 50–
70% confluence.  Fresh complete medium containing 8 μg/mL of polybrene was 
exchanged.  Supernatant containing lentiviral particles (0.5 mL) was then added.  
The fresh complete medium was exchanged 24 h after infection.  The selection was 
started by adding 1.5 μg/mL of puromycin 48–54 h after infection.  Western analysis 
was performed to determine the p23 protein levels after 2–3 passages. 
Transient Transfection 
Cells were grown in 6-well plates overnight (16–18 h) and transfection was 
initiated when cells were about 90–95% confluence.  Cells were transfected with 3 
μg of plasmid (4 μg for HA-GSK3β) and 6 μL of EndoFectin reagent (8 μL for HA-
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GSK3β).  Fresh complete medium was exchanged 24 h after transfection.  HA-
GSK3β and GSK3β shRNA plasmids were transfected for 72 h.  Usually, we initiated 
cell treatment at 70 h post transfection.  pGFP plasmids were transfected for 48 h 
with cell treatment initiated at 48 h post transfection. 
Whole-Cell Lysate Preparation 
Cells were harvested using cold 1xPBS by mechanical scrapping.  Cell pellets 
were resuspended using cold lysis buffer (25 mM HEPES, pH 7.4, 0.4 M KCl, 1 mM 
EDTA, 1 mM DTT, 10% glycerol, 1% NP-40, 1 mM PMSF, and 2 μg/mL of leupeptin) 
of 3 times the volume of cell pellets.  After three cycles of freeze/thaw, lysates were 
kept on ice for 30 min and were then centrifuged at 16,000× g for 10 to 20 min at 4 
C.  The supernatants were defined as whole-cell lysates and were subjected to 
BCA assay to determine the protein concentration. 
Western Blot Analysis 
The protocol for Western blot analysis was described previously (Yang & 
Chan, 2020) with minor modification.  In brief, if 15% instead of 10% acrylamide gels 
were used, they were transferred via full submersion for an additional one hour (3 h 
total) at 4 C.  After the wet transfer, total protein staining was performed using LI-
COR REVERT Total Protein Stain.  Membranes for the examination of LC3B levels 
were dried for at least 40 min and wet with PBS before blocking.  The transferred 
nitrocellulose membranes were blocked in PBS with 5% BSA for 1 h.  Dilutions for 
antibodies were as follows: 1:1000 for anti-p23 JJ3 and anti-LC3B L7543; 1:2000 for 
anti-AHR SA210; 1:5000 for anti-β-actin AM4302; 1:200 for anti-GSK3β 0011-A and 
anti-β-catenin 15B8.  If not specified, Western bands were normalized using total 




RT-qPCR was performed as described previously (Pappas et al., 2018).  In 
brief, when HeLa cells in a 75 cm2 flask reached 90–100% confluence, 5% of cells 
(0.3 mL of 6 mL total cell suspension) were seeded onto each well of a 6-well plate.  
After incubation for 16–18 h, cells were treated with different reagents or transfected 
with the GSK3β shRNA at 90–95% con-fluence.  For Hep3B and MCF-7 cells, when 
cells in 75 cm2 flask reached 95% confluence, 8.3% of cells (0.5 mL of 6 mL total cell 
suspension) were seeded onto each well of a 6-well plate.  After incubation for about 
24 h, cells reached 80–90% confluence and were treated with different reagents.  
After treatment, media were aspirated, and RNA was extracted using the Direct-zol 
kit with TRI reagent.  Reverse transcription was performed for 1 μg of RNA using 
Epicentre MMLV reverse transcriptase.  Quantitative PCR was performed with: 1 μL 
of cDNA from reverse transcription solution, 10 μL of Bio-Rad iTaq SYBR green 
supermix, and 0.8 pmol sequence-specific primers (cyp1a1 primers are OL109, 5′
–GGC CAC ATC CGG GAC ATC ACA GA–3′ and OL110, 5′–TGG GGA TGG 
TGA AGG GGA CGA A–3′; β-actin primers are OL101, 5′-CCA CAC TGT GCC 
CAT CTA GG-3′ and OL102, 5′-AGG ATC TTC ATG AGG TAG TCA GTC AG-
3′) using a Bio-Rad CFX Connect real-time PCR machine with the following 
protocol: 40 cycles of 90 C for 10 s/60 C for 1 min with fluorescence readings 
taken at 60 C.  The 2 −∆∆Cq method (Livak & Schmittgen, 2001) was used to present 
the normalized values. 
Immunoprecipitation and K63-TUBE Far-Western Analysis 
HeLa cells were seeded and cultured overnight in 6-well plates.  Transfection 
of the GSK3β shRNA was initiated when cells reached ~90% confluence and was 
continued for 72 h.  Immunoprecipitation was performed as described previously 
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(Yang & Chan, 2020).  In brief, cells were lysed as described under 4.5 with 4 times 
the volume of pellet size.  Three deubiquitylase inhibitors, namely 1,10-
phenanthroline (5 mM), NEM (10 mM), and PR-619 (50 μM) were added in the lysis 
buffer for immunoprecipitation experiment with K63-TUBE Far-western analysis.  
About 1.5–2.0 milligrams of whole-cell lysates were used for immunoprecipitation of 
AHR using the anti-AHR SA210 antibody (1:200 by volume) for 30 min at room 
temperature.  The pre-equilibrated Protein G Dynabeads (1:200 by volume) were 
then added to each sample with the assay buffer: 25 mM HEPES, pH 7.4, 0.15 M 
NaCl, 1 mM EDTA, 1 mM DTT, 10% glycerol, 0.1% Tween-20, and 1 mg/mL of BSA.  
The samples were incubated with a rotation of 60 rpm overnight at 4 C.  The beads 
were then washed three times for 5 min each with the assay buffer and then eluted 
with electrophoresis sample buffer for SDS-PAGE, followed by Far-western analysis.  
K63-TUBE biotin (1:1000) were incubated with the nitrocellulose membrane for 1 h 
at room temperature and then with IRDye-800 conjugated streptavidin (1:10,000) for 
2 h at room temperature.  The wash step between incubation was the same as in 
Western analysis.  Results were obtained and analyzed using a LI-COR Odyssey 
CLx imaging system. 
Phos-Tag Gel SDS-PAGE 
Whole-cell lysates were treated with 0, 80 units (1 μL), or 400 units (5 μL) of 
λ-PP for 2, 30, or 60 min at 30 C.  To detect the phosphorylated AHR and β-catenin, 
a gel mix containing 7.5% acrylamide, 20 μM phos-tag reagent, and 80 μM ZnCl2 
was prepared to make the phos-tag acrylamide gel, according to the manufacturer’s 
protocol.  Bis-Tris SDS-PAGE system was used with MOPS as the running buffer.  
SDS-PAGE were per-formed at 4 C; 55 volts for the stacking gel and 110 volts for 
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the resolving gel.  Wet transfer was performed at 4 C for 4 h.  Western blot analysis 
was performed as described above. 
 
Table 1 
M1, M2, and M3 Using the pGFP2-N2-AHR Plasmid as the Template for 
QuikChange Mutagenesis 
Target sequence Primer sequence 
S436A-S440A-S444A 
Forward (OL904): 5’-a aat ggc act gct 
gga aaa gac gct gct acc aca gcc act cta 
agc aag g -3’ 
Reverse (OL905): 5’-c ctt gct tag agt 
ggc tgt ggt agc agc gtc ttt tcc agc agt 
gcc att t-3’ 
S689A-S693A-T697A 
Forward (OL906): 5’-gag ttc ccc tac aaa 
gct gaa atg gat gct atg cct tat gca cag 
aac ttt att tcc-3’ 
Reverse (OL907): 5’-gga aat aaa gtt ctg 
tgc ata agg cat agc atc cat ttc agc ttt gta 
ggg gaa ctc-3’ 
S723A-S727A-T731A 
Forward (OL908): 5’-c tac cct atg ggg 
gct ttt gaa cca gcc cca tac ccc gct act tct 
agt t-3’ 
Reverse (OL909): 5’-a act aga agt agc 
ggg gta tgg ggc tgg ttc aaa agc ccc cat 
agg gta g-3’ 
AHR Sequencing part 1 OL859: 5’-TGGCACCAAAATCAACGG 
GACTT-3’ 
AHR Sequencing part 2 OL374: 5’-
CGCCAACATCACCTACGCCAGTC-3’ 
AHR Sequencing part 3 OL375: 5’-
CTCCACTTCAGCCACCATCCATAC-3’ 
AHR Sequencing part 4a  
(For M1, M2 and M3) 
OL376: 5’-
AGGTCACCCAGGGCTCTTTCAAG-3’ 
AHR Sequencing part 4b  
(For M2 confirmation) 
OL910: 5’-GGTCACCCAGGGCTCTTT 
CA-3’ 
AHR Sequencing part 5a  
(For M1, M2 and M3) 
OL858: 5’-
TCGCCGGACACGCTGAACT-3’ 
AHR Sequencing part 5b  






QuikChange II lightning kit was used to perform site-directed mutagenesis.  
All the procedures were performed strictly according to the manufacturer’s protocol.  
For the mutant strand synthesis reaction, 10 ng of the pGFP2-N2-AHR plasmid (J. 
Chen et al., 2021) were used as the template.  Primers are listed in Table 1.  The 
full-length cDNA sequences of all mutant plasmids were confirmed by sequencing 
(Functional Biosciences, Madison, WI).   
Statistical Analysis 
GraphPad Prism 9 software (La Jolla, CA, USA) was utilized for statistical 
analysis.  Two-tailed unpaired t-test and one-way and two-way (or mixed-model) 
ANOVA with Sidak, Tukey or Dunnett tests for multiple comparisons were used to 
determine statistical significance with * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 
0.0001, and ns, not significant (p > 0.05).  Some specific detail is also mentioned in 
the figure legends. 
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CHAPTER 4: SUMMARY AND DISCUSSION 
 
My projects focus on the following two questions: What are the mechanisms 
that control AHR protein levels and what is the role of p23 in AHR regulation.  
Previously, our lab discovered that knocking down of AHR co-chaperone p23 
decreased AHR protein levels in mouse and human cell lines.  I confirmed this 
decreased AHR protein levels caused by p23 knockdown in HeLa cells and used 
HeLa cells to study the degradation mechanism of basal AHR proteins.  
Cycloheximide (CHX) experiments showed that the degradation rate of AHR in 
p23KD HeLa cells is significantly higher than WT HeLa cells (Pappas et al., 2018).  
Treatment with proteasome inhibitor MG132 did not increase but further decreased 
AHR protein levels, suggesting another major protein degradation method: 
autophagy-lysosomal degradation.  In chapter 2, I characterized and confirmed the 
key steps of selective autophagy in AHR protein degradation, including K63-
ubiquitination of AHR, binding of AHR protein to autophagy adaptor protein p62 and 
autophagosome membrane-bound protein LC3B-II in vitro and in situ.  Stable 
knockdown of LC3B also confirmed its involvement in AHR protein degradation.  
Compared to WT HeLa cells, p23KD HeLa cells showed a significantly higher 
autophagic flux, confirming the protective role of p23 in AHR degradation through 
selective autophagy.  Another four human cancer cells lines also showed increase of 
AHR protein levels upon CQ treatment and the interaction between AHR and LC3B, 
as well as AHR and p62.  Comparing to the other four cells lines, the interaction 
between AHR and LC3B in A549 cells is not as sensitive to CQ treatment as other 
cell lines. 
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I also sought for AHR regulation mechanism from post-translational 
modification perspective.  With the reports on the correlation between AHR and 
classical GSK3β substrate β-catenin, and the multiple putative GSK3β recognition 
motif in AHR cDNA sequence, I investigated the role of GSK3β phosphorylation in 
AHR protein regulation.  Alteration of GSK3β activity and expression levels can 
affect AHR protein levels.  This regulation is mediated through autophagy-lysosomal 
degradation pathway.  Surprisingly, GSK3β regulation is not the reason that cause 
increased AHR protein degradation in p23KD HeLa cells.  Instead, p23KD HeLa 
cells are not sensitive to GSK3β modulation, which is AHR-specific and p23-
dependent.  Phosphorylation of AHR was confirmed using Phos-tag gel, showing 
that the intensities of putative phosphorylated AHR bands were subject to the control 
of λ-phosphatase dephosphorylation and GSK3β activity.  Moreover, 
phosphorylation of AHR enhanced the transactivation function of AHR.  
Phosphorylation is not only the signal for ubiquitination and subsequent degradation, 
but it also optimizes AHR function as a transcription factor. 
Based on the current data, there are several questions that need future 
attention: (1) More data are needed to confirm the phosphorylation sites of AHR.  An 
in vitro GSK3β phosphorylation assay followed by LC-MS detection would be helpful 
to confirm the GSK3β-dependent phosphorylation of AHR and verify the proposed 
phosphorylation sites, which may provide more insights to explain the responses of 
two truncated AHR and three AHR mutations to GSK3β inhibition and autophagy 
degradation inhibition.  (2) Is priming required for GSK3β phosphorylation of AHR? If 
so, what kinase(s) are responsible for the priming?  (3) Other than the transactivation 
function of AHR, does phosphorylation affect other AHR roles, such as E3 ligase for 
ER and β-catenin?  (4) What is the E3 ligase responsible for recognition of 
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phosphorylated AHR and the transfer of ubiquitin molecules to AHR?  By targeting 
this ubiquitination step, can AHR protein level be specifically affected and thus help 
with AHR-related disease situations?  (5) What is the underlying mechanism that p23 
can protect AHR from selective autophagy and why lower p23 content leads to 
insensitivity of AHR to GSK3β regulation?  p23 is a highly conserved acidic 
phosphoprotein (Garcia-Ranea, Mirey, Camonis, & Valencia, 2002).  It was first 
discovered as the co-chaperone of HSP90 in the progesterone receptor complex 
(Johnson, Beito, Krco, & Toft, 1994), and has been found in a variety of HSP90 client 
protein complexes.  As a co-chaperone protein, it is reported to help prevent protein 
aggregation in in vitro studies (Bose, Weikl, Bügl, & Buchner, 1996; Freeman, Toft, & 
Morimoto, 1996).  One hypothesis is that p23 may protect AHR from aggregation 
given the fact that the poly-Q region, as in AHR C-terminal sequence, renders the 
protein more prone to aggregation and hence cleared by autophagy.  More data on 
aggregation of AHR proteins would be useful to test this hypothesis.  It is also 
possible that p23 can act as a scaffold protein like Axin in β-catenin construction 
complex.  The interaction among p23, AHR and GSK3β needs to be further 
confirmed.  (6) Data in chapter 2 together with results showed by my colleague 
Jinyun Chen and I (J. Chen et al., 2021) supported that AHR in triple negative breast 
cancer cells can interact with both LC3B and LAMP2A.  However, data showed that 
there is robust CMA going on in HeLa cells using CMA substrate GAPDH as positive 
control (figure 4.1A left), but AHR in HeLa cells is not affected by CMA inducer 6AN 
(figure 2.8) and the interaction with CMA key protein LAMP2A (figure 4.1A right) is 
also much weaker comparing to that of GAPDH.  AHR in HeLa cells is not sensitive 
to LAMP2A anti-sense RNA transfection, which cannot decrease LAMP2 protein 
levels either (could be technical; may consider using LAMP2A-specific shRNA for 
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Figure 4.1.   AHR in HeLa cells is not controlled by chaperone-mediated autophagy 
(CMA) 
knockdown).  The LAMP2 bands of WT HeLa cells showed lower position compared 
to that of MDA-MB-468 cells (figure 4.1B).  The signals that trigger different 
mechanisms of autophagy for AHR degradation remains to be further investigated.   
 
                                                                                                                                       
          .  Proximity ligation assay results showed that (A left panel) GAPDH interacted 
with LAMP2 and this interaction is significantly enhanced by treatment with CMA 
activator 6-aminonicotinamide (6-AN, 100 μM) for 24 h while (A right panel) AHR 
showed minimal interaction with LAMP2.  (B) LAMP2 anti-sense RNA transfection 
(55-hour) cannot alter LAMP2 nor AHR protein levels in HeLa cells.  NT, no 
transfection; Anti/Endo, LAMP2A anti-sense RNA/EndoFectin transfection; 
Empty/Endo, empty plasmid/EndoFectin transfection; Anti/Eco, LAMP2A anti-sense 
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APPENDIX A: METHODOLOGY 
 
The materials and methods used in each chapter are described individually.  
Some details regarding some basic techniques are listed below. 
Generation of HSP90, p23, and LC3B Stable Knockdown Cells 
p23 knockdown HeLa cells were generated using p23-specific shRNA 
(#1475); HSP90 knockdown HeLa cells were generated using the HSP90α-specific 
shRNA (#6, 8563), and LC3B knockdown HeLa cells were generated using the 
MAP1LC3B-specific shRNA #153286 and #151769.  In essence, AD-293 cells 
(about 7 × 105cells) were plated in 5 mL of medium without antibiotics in a 25 cm2 
flask.  After incubation at 37 C and 5% CO2 overnight, cells reached 50%–80% 
confluence.  Fresh medium without antibiotics was exchanged.  Cells were 
transfected using EndoFectin reagent (2:1 DNA ratio) with the plasmids cocktail as 
follows: 2.5 µg of specific shRNA plasmid, 1.875 µg of the pCMV-dR8.2 dvpr 
packaging plasmid, and 0.625 µg of the VSV-G envelope plasmid.  Fresh complete 
medium was exchanged 15 h later.  Medium which contained the virus was collected 
after 24 hours and stored at 4 C.  Another 5 mL of fresh complete medium was 
added to cells and was collected 24 h afterwards. The combined medium was 
centrifuged at 400 g for 5 min to remove any AD-293 cells that were inadvertently 
collected. The resulting supernatant was used for infection.  Store the virus-
containing medium at 4 C for short term use.  Aliquot the media into 1.5 mL tubes 
and freeze down in -80 C for long term storage.  After taken out from -80 C, thaw 
on ice (can only be frozen and thawed once). 
The infection of HeLa cells was performed by first seeding cells in a 25 cm2 
flask to 50%–70% confluence.  Fresh complete medium containing 8 µg/mL of 
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polybrene (dissolved in water; sealed and stored in 4 C) was exchanged.  
Supernatant containing lentiviral particles (0.5–1 mL) was then added.  The fresh 
complete medium was exchanged 24 h after infection.  The selection was started by 
adding 1.5 µg/mL of puromycin 48–54 h after infection.  Include one flask of wild type 
cells for selection as negative control.  For other cell lines, determine the optimal 
puromycin concentration in advance: Seed cells in 12-well plates and culture 
overnight to reach ~80-90% confluence.  Do serial dilution of puromycin at the range 
of 1-10 µg/mL.  Check the cells every day and change fresh media containing 
puromycin if needed.  The optimal concentration should be the one that kill all the 
cells within 3-5 days.  Western analysis was performed to determine the target 
protein levels after 2–3 passages. 
Transient Transfection 
Cells were grown in 6-well plates and transfection was initiated when cells 
were about 90% confluence (after 16-18 hours culture for the best).  The DNA, 
EndoFectin transfection reagent and opti-MEM should be taken out in advance and 
warmed to room temperature.  Cells were transfected with 2.5 µg of DNA and 5 µL of 
EndoFectin reagent (2:1 DNA ratio).  For cells that are difficult to transfect, optimize 
the DNA amount (usually within the range of 2.5-4 µg) and DNA amount: EndoFectin 
volume ratio (try 1:2 to 1:4).  Dilute the DNA in opti-MEM and incubate for 5 minutes 
at room temperature.  During this incubation, dilute EndoFectin with opti-MEM and 
mix well.  Combine the EndoFectin dilution with DNA dilution and incubate for 15-20 
min at room temperature to allow for the formation of DNA-EndoFectin complexes.  
Add the complexes into each well drop by drop avoiding direct adding to the cells.  
Gently rock the plate back and forth for homogenous distribution.  Incubate the cells 
at 37 C.  Exchange fresh complete media after 24h transfection (especially when 
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transfection shows toxicity to cell growth).  Treatment or harvest of cells can be done 
at 48-72h post transfection.  Optimize the time for different plasmid DNA and cell 
lines. 
Whole-Cell Lysate Preparation 
Cell pellets were resuspended using lysis buffer (25 mM HEPES, pH 7.4, 0.4 
M KCl, 1 mM EDTA, 1 mM DTT, 10% glycerol, 1% NP-40, 1 mM PMSF, and 2 
µg/mL of leupeptin) of 2.5-3× volume of cell pellets.  After three cycles of 
freeze/thaw, lysates were kept on ice for 30 min and were then centrifuged at 16,000 
g for 10-20 min (use longer time when pellet size is big) at 4 C. The supernatants 













0 A 0 10 
1:100 BSA 
dilution 
0.05 B 5 5 
0.1 C 10 0 
0.2 D 2 8 
1:10 BSA 
dilution 
0.3 E 3 7 
0.5 F 5 5 
0.7 G 7 3 
1.0 H 10 0 
Note. 1:10 BSA dilution=1:10 dilution of 10mg/mL BSA stock solution.  1:100 BSA 
dilution=1:10 dilution of 1:10 BSA dilution. 
 
Bicinchoninic Acid Protein Assay (BCA) 
Use 96-well plates for BSA standards and samples.  Do duplicates for each 
standard or sample.  The first two column are for standards with concentration 
ranging from 0 to 1.0 mg/mL BSA as shown in Table 2.  The recipe for each 
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concentration is shown in Row1 well content of the table.  The volume for each 
standard or sample is 10 μL.  For samples wells, try to dilute the samples to make a 
final concentration in the range of 0.4-0.7 mg/mL.  I usually do 1:10 dilution.  After 
adding all the standards and samples, add 190 μL BCA reagent mix to each well 
using multichannel pipette and mix well, making a total volume of 200 μL.  BCA 
reagent mix is composed of 98% BCA reagent A and 2% BCA reagent B (by 
volume).  Incubate the plate at 37 C for 30min and determine the absorbance at 
562 nm using Epoch plate reader.  Calculate protein concentration based on 
standard curve and absorbance.  
SDS-PAGE 
We use Bio-Rad Mini-PROTEAN tank for SDS-PAGE with homemade 1.5 mm 
acrylamide gels.  See Table 3 below for 2-gel recipe.  Seal the bottom of the gel 
using 0.7% agarose (14 mg agarose dissolved in 0.5 mL lower Tris and 1.5 mL 
dH2O; microwave to dissolve and solidify for about 10 min).  Pouring the running gel 
on top of the agarose layer until the top surface reach ~1.5 cm to the top edge of the 
short glass; seal by carefully and slowly adding water on top to give a horizonal gel 
surface.  Let the gel stand for 30-60 min at room temperature until a clear line 
emerge between the water layer and the running gel.  Pour the stacking gel and 
insert a 15-well of 10-well comb according to experiment design.  Let the gel solidify 
for another 4-5 hours at room temperature. Wrap the gel with water and store at 4 C 
for future use.  Running condition: ~110 V for the stacking gel; ~180 V for the 
running gel (the lower voltage, the lower temperature, which may help improve the 
resolution and avoid distortion. Use 200 V maximal).  Use 350 mL 1x TGS running 
buffer for the inner and outer compartment of tank.  Stop running util the dye front 
reach ~2-5mm to the bottom of the gel. 
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Table 3 
SDS-PAGE Gel Recipe (2 gels) 
 Running gel Stacking gel 
 10% 12% 15%  
dH2O 8.2 mL 6.9 mL 4.8 mL 3.4 mL 
Acrylamide/Bis 
(30/0.8) 
6.7 mL 8 mL 10.1 mL 0.575 mL 
Buffer (Tris) 5mL (lower Tris) 
1.25 mL 
(upper Tris) 
10% AP 100 μL 50 μL 
TEMED 10 μL 5 μL 
Note. Percentage of the gel is based on the target protein size. 
 
Li-COR Western Analysis 
Based on BCA assay result, prepare samples for SDS-PAGE with 20-40 μg 
total protein loaded (determine the optimal loading amount by doing serial dilution).  
Add HEDG buffer to get similar volume of samples.  Mix the lysate sample 1:1 (v/v) 
with 1x treatment buffer.  Vortex completely and heat at 95 C for 1.5-3 min 
(depending on the volume of the samples).  Briefly centrifuge to collect the samples 
at the bottom, which is ready for SDS-PAGE.  Minimize loading time to reduce the 
diffusion of samples to avoid distortion of bands.  Choose the percentage of the gel 
depending on the molecular weight of target proteins.  Pre-wet the filter paper and 
nitrocellulose membrane before wet transfer.  Set up the polyacrylamide gel-
nitrocellulose membrane pair “sandwich” as illustrated in Figure A1.  Transfer for 
~120 min using 300 mA setting at 4 C.  Fifteen percent acrylamide gels were 
transferred for 3h at 4 C.  After the wet transfer, total protein staining was performed 
using LI-COR RevertTM 700 Total Protein Stain.  Rinse the membrane in dH2O and 
incubate in ~ 5 mL stain solution with gentle shaking.  Decant the stain solution and 
rinse the membrane twice with Wash solution, 30 sec each time.  Rinse with water 
and proceed to imaging using the 700 nm channel.  After imaging, incubate with 
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Figure A1.  Filter paper-polyacrylamide gel-nitrocellulose membrane sandwich 
setup illustration 
Revert solution 5-10 min.  Rinse with water again and the membrane is ready to 
proceed for blocking.  Membranes for the examination of LC3B levels for autophagic 
flux were dried overnight (membranes for small molecular weight proteins should be 
dried for at least 1 hour to improve the quantification accuracy; keep the drying time 
consistent; total protein stain can be done before or after dry process) and wet with 
PBS before total protein staining and blocking.  The transferred nitrocellulose 
membranes were blocked in PBS with 5% BSA for 1 h.  Incubate with primary 
antibody overnight in 4 C.  Wash 5 min × 5 with 1x PBST before proceeding to 
secondary antibody incubation (2 h at room temperature).  Wash the membrane as 
previous.  The last time wash should be PBS to lower the background signal brought 
by Tween-20.  Dry the membrane and proceed to imaging.  If not specified, Western 
bands were normalized using total protein stain.  Results were obtained and 
analyzed using an LI-COR Odyssey CLx imaging system. 
 
 
                                                                                                                                           

























Compared to conventional Laemmli SDS-PAGE described above, the Zn2+-
Phos-tagTM SDS-PAGE used the neutral Bis-Tris gel system to separate 
phosphorylated and unphosphorylated proteins for better resolution.  After 
optimization based on sample type (e.g., whole cell lysate that contains various 
phosphorylated and unphosphorylated proteins needs lower concentration of phos-
tag acrylamide) and target protein size (according to the manual, 6% acrylamide gel 
is recommended for proteins bigger than 60 kDa.  I increased the percentage to 
7.5% for easier handle of the soft gel).  The method to pour the gel is the same as 
conventional acrylamide gel; just the recipe is different (Table 4).  I prepared gel 
freshly before use (let the gel solidify for 5.5 h in total and wrap in water and put in 4 
C for 30 min).  The manual recommended the molar ratio of metal ion (ZnCl2) to 
phos-tag acrylamide in the gel starting at 1:2 and I increased to 1:4 for better capture 
of phosphorylated proteins.  Used 15 μM phos-tag for freshly prepared phos-tag 
acrylamide solution and increased to 20 μM after the stock solution being stored at 4 
C for several weeks. 
Sample preparation were similar as conventional SDS-PAGE.  Add 2 mM 
ZnCl2 to the sample before loading (to reduce the effects caused by EDTA in the 
lysis buffer).  MOPS were used as the running buffer.  SDS-PAGE were performed 
at 4 C; 55 volts for the stacking gel and 110 volts for the resolving gel.  Wet transfer 
was performed at 4 C for 4 h (add 0.175% SDS in the wet transfer buffer; change 
ice box in the tank every 1-1.5 hours to make sure the buffer stays cool).  Dry the 
membrane for 30 min before proceeding to blocking.  Western blot analysis was 




Zn2+-Phos-tagTM SDS-PAGE Gel Recipe (1 gel) 
7.5% resolving gel 
20 μM phos-tag 
Phos-tag gel Conventional gel Stacking gel 
dH2O 4.825 mL 4.945 mL 1.475 mL 
Acrylamide/Bis 
(30/0.8) 
2.5 mL 2.5 mL 0.375 mL 
pH 6.8 Bis-Tris buffer 2.5 mL 2.5 mL 0.625 mL 
5 mM phos-tag 
solution 
40 μL / / 
10 mM ZnCl2 
solution 
80 μL / / 
10% AP 50 μL 50 μL 25 μL 
TEMED 5 μL 5 μL 2.5 μL 
Total 10 mL 10 mL 2.5 mL 
 
Lambda Phosphatase Experiment 
The reaction of λ-phosphatase dephosphorylation was set up as follow: 5 μL 
10x Lambda phosphatase buffer + 5 μL 10x MnCl2 + 133.33 μg whole cell lysate + 
water to reach a total volume of 50 μL.  Mix well and aliquot 16.6 μL into three 
RNase-free 0.2 mL PCR tubes and incubate at 30 C for 2, 30 and 60 min using the 
PCR thermocycler.  Take 15 μL (equals to 40 μg of protein) to load. 
RT-qPCR 
RNA extraction.  Before experiments, briefly centrifuge all kit components 
stored in -20 C.  Centrifuge to collect contents at the bottom of the tube.  For all the 
steps performed, use DNase/RNase-free filter tips.  Lyse cells with TRI reagent.  I 
always lyse cells fresh in 12-well or 6-well plate.  Can also collect the cells and 
freeze in -80 C before lysing.  See Direct-zol kit manual for the corresponding 
volume of TRI reagent used for different size of samples.  All the centrifuge steps 
during RNA extraction are 10,000-16,000 g (I usually do 16,000 g) at room 
temperature.  For 12-well plate sample, add 400 µL TRI reagent per well and mix 
well by pipetting.  Proceed to RNA Purification.  Add an equal volume of ethanol (95-
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100%) directly to one volume sample in TRI.  Mix well by inverting and vortex.  Load 
the mixture into a column in a collection tube.  Centrifuge 30 sec.  Transfer the 
column into a new collection tube and perform in-column DNase I treatment 
(recommended).  Wash the column with 400 µL RNA Wash Buffer.  Centrifuge 30 
sec and discard the flow through.  Prepare DNase I reaction mix in a clean tube 
(amount is per column): 5 µL DNase I (6 U/µL), 75 µL DNA Digestion Buffer.  Mix by 
gentle inversion.  Add 80 µL of the mix per column directly to the column matrix.  
Incubate at room temperature for 15 min and then centrifuge for 30 sec.  Add 400 µL 
Direct-zol RNA PreWash to the column and centrifuge for 30 sec.  Discard the flow 
through and repeat this step.  Add 700 µL RNA Wash Buffer to the column and 
centrifuge of 2 min to ensure complete removal of the wash buffer.  Discard the flow 
through and transfer the column to a RNase-free tube.  Add 50 µL DNase/RNase-
free water directly to the column matrix and centrifuge for 1 min.  Alternatively, for 
more concentrated RNA, use ≥ 25 µL elution.  Quantify with nanodrop.  If not 
proceed to reverse transcription immediately, add RNase inhibitor 0.5 µL per tube 
and store at -80 C.   
Epicentre MMLV reverse transcription.  Denature the RNA samples and 
anneal the primers.  For each reaction, combine the following components on ice in 
a RNase-free 0.2 mL PCR tube: 10 µL total reaction volume= 0.4 µL random primer 
+ 100 pg-1 µg (use 0.5-1 µg for lower Cq number) + RNase-free water.  Incubate at 
65 C for 2 min and chill on ice (set as 4 C) for at least 1 min in the thermocycler.  
Briefly centrifuge and combine with the following components on ice for one reaction 
(total volume would be 20 µL): 3 µL RNase-free water, 2 µL 10x MMLV buffer, 2 µL 
100 mM DTT, 0.5 µL ScriptGuard RNase inhibitor, 2 µL dNTP mix (2.5 mM), 0.5 µL 
MMLV high performance reverse transcriptase.  Use the PCR thermocycler to 
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perform the protocol: 10 min room temperature followed by 37 C 60 min; terminate 
the reaction by heating at 85 C for 5 min and then 4 C for at least 1 min.  
Centrifuge briefly.  The cDNA can be used immediately for real-time PCR or stored 
at -20 C for future use. 
Quantitative PCR (qPCR).  qPCR was performed with 1 μL of cDNA from 
reverse transcription solution, 10 µL of Bio-Rad iTaq SYBR green supermix, and 0.8 
pmol sequence-specific primers using a Bio-Rad CFX Connect real-time PCR 
machine with the following protocol: 40 cycles of 90 C for 10 s/60 C for 1 min with 
fluorescence readings taken at 60 C.  The 2-ΔΔCq method was used to present the 
normalized values.  For RT2 Profiler PCR Array, reverse transcription was performed 
with 0.5 μg of RNA using Epicentre MMLV reverse transcriptase.  PCR master mix 
(1,350 μL of Bio-Rad iTaq SYBR green supermix, 102 μL of cDNA synthesis 
solution, and 1,248 μL of RNase-free water) was prepared and an aliquot of 25 μL 
was added to each well of the RT2 Profiler PCR Array plate.  A Bio-Rad CFX 
Connect real-time PCR machine was used with the following protocol: 95 C for 10 
min, followed by 40 cycles of 95 C for 15 sec/60 C for 1 min (ramp rate between 95 
C to 60 C step was set as 1 C /sec).  Data analysis was performed at Qiagen 
GeneGlobe Data Analysis Center (www.qiagen.com/shop/genes-and-pathways/data-
analysis-center-overview-page). 
Immunoprecipitation and Co-Immunoprecipitation Experiments 
Cells were lysed with the method described under whole cell lysate 
preparation.  Three deubiquitylase inhibitors, namely 1,10-phenanthroline (5 mM), 
NEM (10 mM), and PR-619 (50 μM) were added in the lysis buffer for 
immunoprecipitation experiment with K48- and K63-TUBE Far-western analysis.  
One to two milligrams of whole-cell lysates (about one to two 75 cm2 flasks or one to 
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two 6-well plates of cells) were used for immunoprecipitation (IP) and co-
immunoprecipitation (co-IP) of AHR using anti-AHR antibody SA210 (1:200 by 
volume) or anti-AHR antibody A-3x (1:100 by volume for AHR–p62 co-IP) for 30 min 
at room temperature.  When incubating, pre-equilibrate protein G magnetic beads at 
room temperature as follows: (1) Before taking out beads, shake well to homogenize 
the solution with beads.  Aliquot needed volume of beads slurry into GeneMate 
microfuge tubes (the tube walls need to be thin enough for magnet).  Add 0.5 mL of 
water.  Magnet 1 min and discard supernatant.  (2) Repeat this for three more times 
(gently tap to mix the beads in water).  (3) Wash with IP buffer, following steps in (1).  
IP buffer recipe: 25 mM HEPES, pH 7.4, 1 mM EDTA, 1 mM DTT, 10% glycerol, 
0.15 M NaCl, 0.1% Tween-20 for IP (0.05% Tween-20 for co-IP).  For co-IP, add 
tween-20 only for washing steps to preserve more interaction, depending on the 
signal/background noise results.  Add the samples and 1 mg/mL of BSA to the pre-
equilibrated Protein G Dynabeads (1:200 by volume) and q.s. with IP buffer to 1-1.2 
mL.  The samples were incubated with a rotation of 60 rpm overnight (16-18h) at 4 
C.  The beads were then washed three times for 5 min each with 1 mL IP buffer and 
then eluted with 35-40 μL electrophoresis sample buffer for SDS-PAGE, followed by 
LI-COR Western analysis. 
K48- and K63-TUBE and Far-Western Analysis 
HeLa cells were seeded and cultured overnight in a 75 cm2 flask and 
harvested after treatment, if needed, with cold PBS by mechanical scraping.  Cell 
lysates were obtained using a lysis buffer (see whole cell lysate preparation) with a 
4× volume of the cell pellet.  Immunoprecipitation was performed as described 
above, followed by Far-western analysis.  K48- or K63-TUBE (1:1,000) were 
incubated with the nitrocellulose membrane for 1 h at room temperature.  Wash with 
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1x PBST 5 min for 5 times and then incubate with IRDye-800cw conjugated 
streptavidin (1:10,000) for 2 h at room temperature.  The blocking step and wash 
steps between and after incubation were the same as in LI-COR Western analysis.  
Results were obtained and analyzed using an LI-COR Odyssey CLx imaging system.  
Membrane was scanned wet.  After placing the membrane on the working area of LI-
COR, scroll the membrane to make to membrane tightly placed flat on the glass top. 
Proximity Ligation Assay 
Cells were seeded on round microscope glass coverslips placed in wells of a 
12-well plate and grown to about 80% confluence.  Cells were then rinsed with PBS 
twice and incubated with ice-cold 100% methanol for 5 min.  After one rinse with 
PBS, cells were ready for proximity ligation assay using Duolink in situ kit.  Cells 
were first incubated with Duolink blocking solution (40 μL) at 37 C for 60 min, 
followed by incubation with the two antibodies (in Duolink antibody diluent) used for 
interaction study (40 μL) at 37 C for 60 min using the following dilution: mouse anti-
AHR A-3x (1:100), rabbit anti-p62 (1:100), and rabbit anti-LC3B (1:100).  Then, 5 
min×3 washes using wash buffer A were performed with gentle shaking.  Samples 
were next incubated with Duolink probes.  Briefly mixed the PLUS and MINUS 
probes by vortex and did 1:5 dilution using Duolink antibody diluent.  Aspirate all the 
residual wash buffer and apply 40 μL Duolink probes.  Incubated the samples at 37 
C for 60 min.  Wash the coverslip 4×5 min at room temperature with 1×wash buffer 
A.  Added the ligase to the 1×ligation buffer at 1:40 dilution and mix well immediately 
before adding to samples.  Incubated at 37 C for 30 min.  Wash the coverslip 3×5 
min at room temperature with 1×wash buffer A.  Added the polymerase to the 
1×amplification buffer at 1:80 dilution and mix well immediately before adding to 
samples.  Both the ligase and polymerase should be temporarily stored in the 
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freezing block.  The amplification buffer is light sensitive.  All solutions and samples 
containing the buffer should be protected from light.  Incubated at 37 C for 100 min.  
Final wash steps included 2×10 min wash with 1× wash buffer B and then 0.01× 
wash buffer B for 2 min at room temperature (keep from light).  Nucleus staining was 
performed by adding 1 μg/mL of DAPI (dilute freshly from 1000x stock solution; keep 
from light) in water to cells for a 1 min incubation.  Coverslips were rinsed with 1× 
PBS and then mounted using ~6 μL of PBS and were sealed with nail polish.  
Samples were viewed using a KEYENCE BZ-X700 fluorescence microscope.  Wait 
for ~15 minutes before analyzing in the fluorescence microscope, using at least a 





APPENDIX B: HOMEMADE REAGENT RECIPE 
 
The recipes of homemade reagent mentioned in APPENDIX B were listed below. 
 
Lower Tris Buffer (1.5 M Tris) 
181.7 g Tris in 800 mL H2O. Adjust pH to 8.8 and qs 1000 mL. 
 
Upper Tris Buffer (0.5 M Tris) 
30.3 g Tris base in 400 mL H2O. Adjust pH to 6.8 and qs 500 mL. 
pH 6.8 Bis-Tris buffer (1.4 mol/L Bis-Tris): Bis-Tris base 29.9 g in 50 mL 
water.  Then add 5 mL concentrated HCl (12M) and q.s. to 100 mL (no need to 
adjust pH).  Keep at 4 C in the dark. 
 
10 mM ZnCl2 Solution  
14 mg in 10 mL water.  Filter to remove impurities.  Prepare just before use. 
 
10% AP  
1 g ammonium persulfate in 10 mL dH2O.  Aliquot to 0.5 mL fractions and 
stored at -20 C.  After taken out, do not put back (avoid freeze-thaw).  Use within 
two weeks. 
 
Acrylamide/Bisacrylamide 30/0.8 (30% acrylamide/ 0.8% Bisacrylamide) 
120 g acrylamide + 3.2 g Bisacrylamide, qs 400 mL (dissolve in ~200 mL H2O 
then qs 400 mL) 
Caution: only use special spatula (only for acrylamide and Bis); weight in 
hood; wear gloves, mask and lab coat.  
 
HEDG Buffer 
25 mM HEPES (5.96 g) + 1 mM EDTA (2 mL of 0.5 M EDTA) + 1 mM DTT 
(154.25 mg) + 10% glycerol (100 mL), qs with water to 1 L.  Adjust pH to 7.4. 
 
100 mM PMSF Stock 
Dissolve PMSF 17.4 mg into 1 mL isopropanol.  Aliquot to 1 mL and store at -
20 C. 
 
Treatment Buffer (1x) Minus βME 
6.3 g or 5 mL glycerol + 6.25 mL upper Tris buffer + 20 mL 10% SDS + 4 mL 
0.25% Bromophenol Blue, qs with water to 50 mL.  Take 950 μL and add 50 μL βME 
to make ready-to-use 1x treatment buffer. 
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MOPS Running Buffer 
Tris base 4.242 g + MOPS 7.322 g + 0.1855 g NaHSO3 (sodium bisulfite) + 
3.5 mL 10% (w/v) SDS solution and q.s. to 350 mL.  Prepare just before use. 
 
Wet Transfer Buffer 




APPENDIX C: SUPPLEMENTARY TABLE FOR CHAPTER 2 
 
Table 5 
A List of the 84 Autophagy-Related Genes Plus 5 Housekeeping Reference Genes 




NM_005163 AKT1 V-akt murine thymoma viral oncogene homolog 1 
NM_017749 AMBRA1 Autophagy/beclin-1 regulator 1 
NM_000484 APP Amyloid beta (A4) precursor protein 
NM_031482 ATG10 
ATG10 autophagy related 10 homolog (S. 
cerevisiae) 
NM_004707 ATG12 
ATG12 autophagy related 12 homolog (S. 
cerevisiae) 
NM_017974 ATG16L1 ATG16 autophagy related 16-like 1 (S. cerevisiae) 
NM_033388 ATG16L2 ATG16 autophagy related 16-like 2 (S. cerevisiae) 
NM_022488 ATG3 ATG3 autophagy related 3 homolog (S. cerevisiae) 
NM_052936 ATG4A ATG4 autophagy related 4 homolog A (S. cerevisiae) 
NM_178326 ATG4B ATG4 autophagy related 4 homolog B (S. cerevisiae) 
NM_178221 ATG4C ATG4 autophagy related 4 homolog C (S. cerevisiae) 
NM_032885 ATG4D ATG4 autophagy related 4 homolog D (S. cerevisiae) 
NM_004849 ATG5 ATG5 autophagy related 5 homolog (S. cerevisiae) 
NM_006395 ATG7 ATG7 autophagy related 7 homolog (S. cerevisiae) 
NM_024085 ATG9A ATG9 autophagy related 9 homolog A (S. cerevisiae) 
NM_173681 ATG9B ATG9 autophagy related 9 homolog B (S. cerevisiae) 
NM_004322 BAD BCL2-associated agonist of cell death 
NM_001188 BAK1 BCL2-antagonist/killer 1 
NM_004324 BAX BCL2-associated X protein 
NM_000633 BCL2 B-cell CLL/lymphoma 2 
NM_138578 BCL2L1 BCL2-like 1 
NM_003766 BECN1 Beclin 1, autophagy related 
NM_001196 BID BH3 interacting domain death agonist 
NM_004052 BNIP3 BCL2/adenovirus E1B 19kDa interacting protein 3 
NM_004346 CASP3 Caspase 3, apoptosis-related cysteine peptidase 
NM_001228 CASP8 Caspase 8, apoptosis-related cysteine peptidase 
NM_004064 CDKN1B Cyclin-dependent kinase inhibitor 1B (p27, Kip1) 
NM_000077 CDKN2A 
Cyclin-dependent kinase inhibitor 2A (melanoma, 
p16, inhibits CDK4) 
NM_000086 CLN3 Ceroid-lipofuscinosis, neuronal 3 
NM_001908 CTSB Cathepsin B 
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NM_001909 CTSD Cathepsin D 
NM_004079 CTSS Cathepsin S 
NM_003467 CXCR4 Chemokine (C-X-C motif) receptor 4 
NM_004938 DAPK1 Death-associated protein kinase 1 
NM_018370 DRAM1 DNA-damage regulated autophagy modulator 1 
NM_178454 DRAM2 DNA-damage regulated autophagy modulator 2 
NM_004836 EIF2AK3 Eukaryotic translation initiation factor 2-alpha 
kinase 3 
NM_182917 EIF4G1 Eukaryotic translation initiation factor 4 gamma, 1 
NM_000125 ESR1 Estrogen receptor 1 
NM_003824 FADD Fas (TNFRSF6)-associated via death domain 
NM_000043 FAS Fas (TNF receptor superfamily, member 6) 
NM_000152 GAA Glucosidase, alpha; acid 
NM_007278 GABARAP GABA(A) receptor-associated protein 
NM_031412 GABARAPL
1 
GABA(A) receptor-associated protein like 1 
NM_007285 GABARAPL
2 
GABA(A) receptor-associated protein-like 2 
NM_004964 HDAC1 Histone deacetylase 1 
NM_006044 HDAC6 Histone deacetylase 6 




HSP90AA1 Heat shock protein 90kDa alpha (cytosolic), class 
A member 1 
NM_006597 HSPA8 Heat shock 70kDa protein 8 
NM_002111 HTT Huntingtin 
NM_000619 IFNG Interferon, gamma 
NM_000618 IGF1 Insulin-like growth factor 1 (somatomedin C) 
NM_000207 INS Insulin 
NM_00114580
5 
IRGM Immunity-related GTPase family, M 
NM_005561 LAMP1 Lysosomal-associated membrane protein 1 
NM_181509 MAP1LC3A Microtubule-associated protein 1 light chain 3 
alpha 
NM_022818 MAP1LC3B Microtubule-associated protein 1 light chain 3 
beta 
NM_001315 MAPK14 Mitogen-activated protein kinase 14 
NM_002750 MAPK8 Mitogen-activated protein kinase 8 
NM_004958 MTOR Mechanistic target of rapamycin 
(serine/threonine kinase) 
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NM_003998 NFKB1 Nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 1 
NM_000271 NPC1 Niemann-Pick disease, type C1 
NM_002647 PIK3C3 Phosphoinositide-3-kinase, class 3 
NM_002649 PIK3CG Phosphoinositide-3-kinase, catalytic, gamma 
polypeptide 
NM_014602 PIK3R4 Phosphoinositide-3-kinase, regulatory subunit 4 
NM_006251 PRKAA1 Protein kinase, AMP-activated, alpha 1 catalytic 
subunit 
NM_000314 PTEN Phosphatase and tensin homolog 
NM_130781 RAB24 RAB24, member RAS oncogene family 
NM_000321 RB1 Retinoblastoma 1 
NM_005873 RGS19 Regulator of G-protein signaling 19 
NM_003161 RPS6KB1 Ribosomal protein S6 kinase, 70kDa, polypeptide 1 
NM_000345 SNCA Synuclein, alpha (non A4 component of amyloid 
precursor) 
NM_003900 SQSTM1 Sequestosome 1 
NM_000660 TGFB1 Transforming growth factor, beta 1 
NM_004613 TGM2 Transglutaminase 2 (C polypeptide, protein-
glutamine-gamma-glutamyltransferase) 
NM_153015 TMEM74 Transmembrane protein 74 
NM_000594 TNF Tumor necrosis factor 
NM_003810 TNFSF10 Tumor necrosis factor (ligand) superfamily, member 
10 
NM_000546 TP53 Tumor protein p53 
NM_003565 ULK1 Unc-51-like kinase 1 (C. elegans) 
NM_014683 ULK2 Unc-51-like kinase 2 (C. elegans) 
NM_003369 UVRAG UV radiation resistance associated gene 
NM_017983 WIPI1 WD repeat domain, phosphoinositide interacting 1 
NM_001101 ACTB* Actin, beta 
NM_004048 B2M* Beta-2-microglobulin 
NM_002046 GAPDH* Glyceraldehyde-3-phosphate dehydrogenase 
NM_000194 HPRT1* Hypoxanthine phosphoribosyltransferase 1 
NM_001002 RPLP0* Ribosomal protein, large, P0 
Note.  Asterisk (*) indicates a housekeeping gene. 
 
